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1ABSTRACT 
TRPM2 is a calcium permeable channel activated by ADPR metabolites and oxidative 
stress. TRPM2 contributes to neuronal injury in the brain caused by stroke and cardiac arrest 
among other diseases including cancer, inflammation, and pain. However, the lack of specific 
inhibitors hinders the study of TRPM2 in pathophysiology. Our lab designed tat-M2NX to 
prevent ligand binding and TRPM2 activation. We performed a structure-activity relationship 
(SAR) study through mutagenesis of tat-M2NX to determine the antagonistic mechanism on 
TRPM2 using whole-cell patch clamp and Ca2+ imaging in human embryonic kidney (HEK) 293 
cells with stable human TPRM2 expression. We show that tat-M2NX inhibits 75% of TRPM2 
channel currents at 0.5µM and 90% of TRPM2 currents at concentrations of 2, 5, and 10μM. 
Moreover, tat-M2NX is a potent antagonist with an IC50 of 396nM. Our results from tat-M2NX 
mutagenesis indicate that specific residues within the tat-M2NX C-terminus are required to 
confer antagonism on TRPM2.  
In light of negative clinical trials for neuroprotective agents for cardiac arrest and stroke, 
we developed a new approach aimed at reversing synaptic dysfunction. Cardiac arrest/ 
cardiopulmonary resuscitation (CA/CPR) in mice was used to investigate cognitive deficits and 
the role of the calcium-permeable ion channel transient receptor potential-M2 (TRPM2) in 
ischemia-induced synaptic dysfunction. Our data indicates that absence (TRPM2-/-) or acute 
inhibition of TRPM2 channels with tatM2NX reduced hippocampal cell death in males only, but 
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prevented synaptic plasticity deficits in both sexes. Remarkably, administration of tatM2NX 
weeks after injury reversed hippocampal plasticity and memory deficits. Finally, TRPM2-
dependent activation of calcineurin-GSK3β pathway contributes to synaptic plasticity 
impairments. These data suggest persistent TRPM2 activity following ischemia contributes to 
impairments of the surviving hippocampal network and that inhibition of TRPM2 channels at 
chronic time points may represent a novel strategy to improve functional recovery following 
cerebral ischemia that is independent of neuroprotection. Therefore, the peptide tat-M2NX 
represents a new tool for the study of TRPM2 function in cell biology, also to enhance our 
understanding of TRPM2 in disease. 
The form and content of this abstract are approved. I recommend its publication. 
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CHAPTER I 
INTRODUCTION 
Scope and significance 
Cerebral ischemia in the form of cardiac arrest (CA) and stroke represent a major clinical 
problem in the United States due to an annual incidence of 600,000 and 795,000 people, 
respectively (Benjamin, Muntner et al. 2019). A significant number of patients with CA exhibit 
motor, cognitive and memory, and executive functional deficits leading to long-term disabilities 
(Grubb, Fox et al. 2000, Moulaert, Verbunt et al. 2009, Mateen, Josephs et al. 2011). Many 
therapies treat motor impairments due to cortical injury. However, the hippocampus brain region 
is sensitive to cerebral ischemia and most vulnerable to neuronal loss (Horn and Schlote 1992). 
Over 50% of CA1 neurons are loss in hippocampal ischemic injury in human autopsy samples 
(Hatanpaa, Raisanen et al. 2014). Moreover, age-dependent cognitive decline is associated to 
loss of BBB integrity in the hippocampus (Montagne, Barnes et al. 2015). In the last decades, a 
number of preclinical and clinical studies have focused in neuroprotection or preservation of 
sensitive neuronal populations. This objective has proven difficult and many clinical trials failed 
to provide clinical benefit in patients, despite promising results in preclinical ischemia models 
(Ginsberg 2009). Thus far, therapeutic strategies to treat memory impairment in cerebral 
ischemia remain relatively unexplored with little improvement clinically. In particular, cell death 
of the hippocampal CA1 region and dysfunction of the remaining neuronal network are linked to 
these memory deficits (Neumann, Cohan et al. 2013). One of the cellular and molecular 
correlates of learning and memory is synaptic plasticity in the brain, defined as an enhancement 
or weakening of synapses in response to activity. Calcium (Ca2+)-dependent signaling mediates 
the molecular mechanisms encompassing synaptic plasticity.  
Among Ca2+ signals in neurons, resides the oxidative stress-activated Transient 
Receptor Potential Melastatin 2 (TRPM2) channel. TRPM2 is a non-selective cation channel, a 
well-established contributor to neuronal cell death following oxidative stress insults that provides 
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a significant source of intracellular Ca2+ (Hara, Wakamori et al. 2002, Jia, Verma et al. 2011, 
Verma, Quillinan et al. 2012, Alim, Teves et al. 2013). Furthermore, Ca2+ influx via TRPM2 
mediates heterogeneous signaling and cellular functions in different organs (neurons, 
pancreatic β cells, and tumor cells). In neurons, expression and function of TRPM2 requires N-
methyl-D-aspartate glutamate receptor (NMDAR) and voltage-gated calcium channels (VGCC) 
activity. Increasing evidence suggests that TRPM2 downstream signaling inhibits the NMDAR 
signaling via glycogen synthase kinase 3 beta (GSK3β) de-phosphorylation, thus potentially 
providing a mechanistic feedback loop that contributes to impaired synaptic plasticity. Therefore, 
the goal of this dissertation is to understand TRPM2 activity in hippocampal function following 
global cerebral ischemia. In whole, this dissertation examines the pharmacological properties of 
a novel TRPM2 inhibitor tatM2NX (Chapter II), modifications of TRPM2 channel activity leading 
to memory deficits in global cerebral ischemia (Chapter III), and future directions addressing the 
molecular mechanism underlying long-term potentiation (LTP) impairment via TRPM2 signaling 
(Chapter V).  
Cerebral ischemia 
Cardiac arrest (CA) results in a diffuse (global) injury in wide areas of the brain due to 
the transient lack of oxygen and nutrients flowing to the brain. A plethora of events originates 
within minutes to days resulting in acute and delayed pathological hallmarks. Cessation of blood 
flow causes cytotoxic effects that lead to neuronal death due to hypoxic-ischemic injury 
(Sanganalmath, Gopal et al. 2017). Therefore, time of intervention in CA is critical to reduce the 
number of sensitive populations that undergo cell death including hippocampal pyramidal 
neurons and cortical layers III, V, VI, cerebellar Purkinje cells, and basal ganglia 
(Sanganalmath, Gopal et al. 2017). Out-of-hospital CA (OHCA) patients are more likely to have 
neurological deficits compared to in-hospital CA patients likely due to organ damage after 
prolonged periods of no circulation before receiving appropriate treatment (Kuschner 2019). 
Moreover, there is a poor survival of OHCA overall, and particularly in low-income 
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neighborhoods (Moulaert, Verbunt et al. 2009, Sasson, Magid et al. 2012). Unfortunately, global 
cerebral ischemia preclinical models have not successfully translated on to therapies.  
CA remains one of the leading causes of death and long-term cognitive and memory 
deficits affecting the elderly population (Girotra, Nallamothu et al. 2012). Approximately, half of 
OHCA patients present memory deficits along with decreased amygdala-hippocampal and total 
brain volume (Grubb, Fox et al. 2000). OHCA patients also show reduced ability returning to 
work compared to control patients, and present signs of cognitive difficulties, and other 
neurological sequela (Lilja, Nielsen et al. 2018). These results urge researchers to identify the 
cellular mechanisms involved in cognitive deficits that are affecting outcome in patients following 
CA.  
Neurological post-care treatment after CA may include therapeutic hypothermia and 
neurological measurements to address prognosis and patient survival (Peberdy, Callaway et al. 
2010). However, there are no treatments focusing on cognitive dysfunction after cerebral 
ischemia. This requires a deeper understanding of long-term deficits in areas such as the 
hippocampus beyond the molecular mechanisms involved in loss of ischemic neurons. The 
work of this dissertation aims to fill some of the gaps in knowledge on impaired synaptic function 
after CA. 
Cellular mechanisms 
During CA, lack of blood flow causes oxygen and glucose deprivation in the brain. This 
environment is characterized by reduced ATP generation and dysregulation of cellular 
processes including mitochondrial activity resulting in cell death of neuronal and glial 
populations via necrosis, apoptosis and autophagy (Victor Li 2012). Return of spontaneous 
circulation (reperfusion) leads to intracranial pressure (edema), depolarization, high levels of 
calcium (Ca2+) and other ions (Sanganalmath, Gopal et al. 2017) in conjunction with swelling 
astrocytes, glutamate release, and failure of ionic balance by sodium/proton (Na+/H+) pumps 
(Panickar and Norenberg 2005). Excessive cellular excitation alters Ca2+ homeostasis after 
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cerebral ischemia due to activation of Ca2+ permeable channels and unsustainable Ca2+ uptake 
by organelles. Among the Ca2+ permeable channels are glutamate receptors, VGCC, Na+/Ca2+ 
exchanger, TRP channels, and Acid-Sensing channels (Cross, Meloni et al. 2010). Ca2+ 
overload through these ion channels leads to the overproduction of oxidative radicals causing 
detrimental effects to macromolecules leading to cell death following oxidative stress, 
proteolysis, phosphorylation, and other signaling (Deshpande, Siesjo et al. 1987, Chan 2001).  
The acute phase after cerebral ischemia is characterized by immediate cell death of 
sensitive neuronal populations occurring within minutes to hours. Delayed neuronal death 
(DND) is observed within days (peaks at 3 days) following cerebral ischemia in vulnerable 
populations in the hippocampus, striatum, and cortex in rodents (Abe, Aoki et al. 1995). 
Hippocampal DND is the consequence of lack of ATP to keep ionic balance, a change in 
mitochondrial potential, and oxidative stress activating pro-death signals. Interestingly, oxidative 
stress activates TRPM2 and potentially contributes to a feedforward mechanism to these cell 
death pathways.  
In addition to the cell death pathways mentioned above, inflammation from the local and 
systemic circulation leads to the release of inflammatory signals. There is much controversy as 
to whether the immune response effects are detrimental or beneficial. The immune response 
includes release of cytokines by microglia and induction of adhesion molecules, chemokine 
upregulation, disruption of the blood brain barrier and activation of leukocytes (Kawabori and 
Yenari 2015). Circulating immune cells and resident-microglia respond to brain injury and may 
contribute to cell death. While other responses such as release of matrix metalloproteinases 
(MMPs) are beneficial to induce plasticity and recovery.  
All these responses make cerebral ischemia complex and require the use of preclinical 




The hippocampus is a brain region historically known for its involvement in memory 
acquisition and consolidation, which is more important in context-dependent spatial memory and 
memory storage facilitation for days to weeks (Eric R. Kandel 2000, O'Keefe 2007). The 
hippocampal formation structure is subdivided into CA1, CA2, CA3, subiculum and dentate 
gyrus regions. Each region has unique and diverse roles in associative, declarative, social, and 
recall memory. The hippocampus is also involved in emotional behavior via reciprocal 
connections with amygdala, movement responses via ventral striatum, and hypothalamic 
hormone release (Anand and Dhikav 2012). 
 The hippocampus receives polysynaptic and direct intrahippocampal pathways involved 
in learning and memory. Polysynaptic inputs from entorhinal cortex regions from parietal, 
occipital and temporal areas arrive to dentate gyrus and are involved in semantic memory. The 
direct intrahippocampal pathway from temporal cortex is involved in spatial and episodic 
memory through inputs to CA1 hippocampus.  The CA1 hippocampal structure is mainly 
composed of a layer of pyramidal neurons receiving inputs at distal and proximal dendrites from 
ipsilateral and contralateral CA3 axons, also known as Schaffer collaterals. The CA1 
hippocampal neurons also receive projections from entorhinal cortex layer III (perforant path). 
CA1 hippocampal neurons send outputs to the subiculum and deep layers of the entorhinal 
cortex (O'Keefe 2007) (Figure 1.1).  
During development, these hippocampal subregions undergo changes in synaptic 
connectivity shaping the network through neurogenesis and synaptogenesis. In adulthood, the  
hippocampal synapses change structurally based on experience or injury. Synapses in CA1 
pyramidal neurons are heterogeneous receiving excitatory inputs at dendritic spines and 
inhibitory inputs on dendritic shafts in distal dendrites. Most inhibitory inputs terminate in 
proximal dendrites, soma, and initial axonal segment (Megias, Emri et al. 2001). The inhibitory 
inputs control the level of CA1 output while Ca2+ levels in dendrites control responses to 
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plasticity (Megias, Emri et al. 2001). CA1 pyramidal neurons receive inhibitory inputs from a 
number of interneuron sub-populations adding a layer of complexity and regulating preferential 
responses in the network (Lee, Marchionni et al. 2014, Harris, Hochgerner et al. 2018) 
Hippocampal synaptic plasticity 
Basal excitatory function and activity of the hippocampus occurs via activation of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors (AMPAR) and Na+ 
channel generation of action potentials upon activity (O'Keefe 2007). The cellular mechanisms 
taking place in the hippocampus involve pairing of pre- and post-synaptic neuronal stimuli. 
These were initially proposed by Ramón y Cajal (1911) and Hebb (1949) as changes in strength 
of synaptic connections that required timing between the pre- and post-synaptic cleft (Bliss and 
Lomo 1973). Later on, it was discovered that activity dependent alterations in synaptic strength 
are a cellular correlate of learning and memory (Nicoll 2017). One of these modifications, known 
as long-term potentiation (LTP), is an increase in synaptic activity that requires activation by 
multiple players depending on the brain region. LTP is mainly NMDAR-dependent in the CA1 
region of the hippocampus and results from initial depolarization of the post-synaptic cell 
through AMPAR followed by Ca2+ influx through NMDAR (Collingridge, Kehl et al. 1983, Kauer, 
Malenka et al. 1988, Muller, Joly et al. 1988). Ca2+ binding to calmodulin (CaM) and Ca2+-CaM 
kinase II (CaMKII) leads to autophosphorylation of CaMKII and AMPAR insertion at the 
postsynaptic density (PSD) or an increase in their single channel conductance (Kristensen, 
Jenkins et al. 2011, Coultrap, Freund et al. 2014) which together lead to LTP (Hebbian plasticity) 
(Lamsa, Irvine et al. 2007). CaMKII α and β isoforms have distinct roles (Incontro, Diaz-Alonso 
et al. 2018). CaMKIIα kinase activity is required for basal NMDAR and AMPAR activity, and 
induction and maintenance of NMDAR-dependent LTP (Sanhueza, Fernandez-Villalobos et al. 
2011, Barcomb, Hell et al. 2016, Incontro, Diaz-Alonso et al. 2018). These lasting changes in 
synaptic efficacy within the network are input-specific and can last for hours while local synaptic 
modifications occur before changes in plasticity genes take place.     
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 Stimulation paradigms that induce plasticity changes such as theta burst stimulation 
(TBS) paradigms were discovered based on hippocampal theta rhythm and patterns of neuronal 
firing (complex-spikes) (Larson, Wong et al. 1986, Larson and Munkacsy 2015). The first burst 
primes the circuit by disinhibiting the inhibitory gamma-amino-butyric acid (GABA) signals 
allowing subsequent bursts to induce LTP (Larson and Lynch 1986). This theta-bursting is 
observed in spatial memory tasks and odor discrimination (Otto, Eichenbaum et al. 1991), which 
is the protocol used in this work. Learning tasks in rodents show electrical patterns and changes 
in NMDAR similar to LTP after high-frequency stimulation in hippocampal CA1 region (Whitlock, 
Heynen et al. 2006). Early memory consolidation requires NMDAR binding to CaMKII and 
animals with mutations that impair this interaction show deficits in memory recall in a Morris 
Water Maze behavioral task (Halt, Dallapiazza et al. 2012). NMDAR are important for TBS 
induction of LTP in CA1 neurons (Grover, Kim et al. 2009) and increased dendritic spine size 
occurs with augmented AMPAR current, NMDAR activation, and actin polymerization during 
LTP in CA1 neurons (Matsuzaki, Honkura et al. 2004). 
 Hippocampal dysfunction in cerebral ischemia 
Hippocampal function has been revealed through reports of patients such as H.M., who 
presented memory deficits associated with memory retention (consolidation) after complete 
removal of the hippocampus (Eric R. Kandel 2000). This study set precedence for the role of the 
hippocampus in memory. Neurologic deficits such as cognitive and memory impairment result 
from neuronal dysfunction accounting for synaptic plasticity changes as well as the inability of 
surviving neurons to compensate for the loss of function within the network, especially prevalent 
in CA1 hippocampal neurons. Hippocampal CA1 neurons are ideal for studying ischemia 
pathophysiology because they are uniquely susceptible to injury, the hippocampal structure is 
well studied, and the resulting phenotype is predictable in both electrophysiology and behavior. 
Moreover, injury to CA1 hippocampal region is sufficient to cause synaptic plasticity associated 
behavioral deficits in rodents (O'Keefe 2007). In humans, specific lesion to CA1 neurons is 
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accompanied by explicit memory deficits (Rempel-Clower, Zola et al. 1996). Therefore, this 
body of work will focus in CA1 hippocampal neurons after CA.  
Upon moderate ischemic injury, CA1 neurons undergo DND long after ionic imbalance 
has occurred (MacDonald, Xiong et al. 2006). Morphological changes indicative of DND in CA1 
neurons occur 2-3 days after ischemia, with intact cellular organelles to supply energy demands 
with cleavage of structural proteins and mild chromatin compaction (Kirino 2000). Protein 
accumulation due to shut down of protein synthesis and degradation (Ge, Zhang et al. 2012), as 
well as glutamate excitotoxicity and Ca2+ overload contribute to DND (Szydlowska and 
Tymianski 2010). Hippocampal CA1 neurons disappear within 3-4 days after ischemia via 
necrotic death or apoptosis (Martin, Sieber et al. 2000, Cao, Pei et al. 2002). There is evidence 
suggesting that males and females engage these cell-death signaling pathways differently in 
cerebral ischemia (Chauhan, Moser et al. 2017), and will be discussed briefly in this work. 
While many neurons die, the surviving neuronal population exhibits critically 
compromised cell physiology after cerebral ischemia. This occurs, in part, because of their 
cellular ability to balance Ca2+ overload initially generated through NMDAR. Once negative 
feedback loops inactivate NMDAR, other channels like TRPM2 are activated by oxidative stress 
and free radicals (Perraud, Takanishi et al. 2005). However, little is known about hippocampal 
dysfunction after cerebral ischemia and the role of Ca2+ permeable channels like TRPM2 in 
surviving CA1 hippocampal neurons. Cerebral ischemia induced by cardiac arrest/ 
cardiopulmonary resuscitation (CA/CPR), a global ischemia in vivo model, causes LTP 
impairment for up to 30 days as recorded using field excitatory post-synaptic potentials 
(fEPSPs) (Orfila, Shimizu et al. 2014, Dietz, Deng et al. 2016). The LTP impairment is not due 
to loss of NMDARs, which mediate this form of synaptic plasticity (Orfila, McKinnon et al. 2018). 
CA/CPR had no effect on pre-synaptic release (PPR), AMPA/NMDA ratio or overall input-output 
(Orfila, Shimizu et al. 2014, Dietz, Deng et al. 2016). Further, successfully attaining and 
recording EPSPs suggests that there are surviving neurons after CA with functional ion 
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channels. This population of neurons is potentially a pharmacological target at time points 
beyond those limited by neuroprotection.   
Most of the studies so far have focused on structural changes in the hippocampal 
network at acute time points while delayed time points (days-months) are less studied. Acutely, 
there is extensive remodeling of synapses early after (minutes to hours) transient ischemia, a 
great number of synapses are added or grow in size while simultaneous synapse elimination, 
bursting and swelling occurs within 6-24h (Jourdain, Nikonenko et al. 2002, Brown, Wong et al. 
2008). Oxygen-glucose deprivation (OGD) studies in organotypic slices show that the growth 
mechanisms are NMDAR and Ca2+ signaling dependent, suggesting the involvement of LTP 
components in this process (Jourdain, Nikonenko et al. 2002). In a transient ischemic event, 
there is a decrease in the number of spines within 2-24h, along with cell and mitochondrial 
swelling, and initial enlargement of PSD in remaining synapses (Zhang, Boyd et al. 2005). This 
enlargement is observed in remaining synapses after in vivo ischemia at 24h (Brown, Wong et 
al. 2008). Restructuring of spines and dendrites is relatively resistant to the severity of cerebral 
ischemia (Zhang, Boyd et al. 2005). In the hippocampus, the number of CA1 synaptic 
vesicles/presynaptic terminal decreased 60-70% at 7 days, while only 20% of neurons remain 
intact (Kovalenko, Osadchenko et al. 2006), indicating that functional impairment of CA1 
hippocampal neurons following cerebral ischemia exists days after injury.  
Ca2+ permeable channels contribute to homeostatic dysregulation and vulnerability of 
CA1 hippocampal neurons to cell death and network dysfunction that leads to synaptic plasticity 
impairment (Deshpande, Siesjo et al. 1987, Murphy, Li et al. 2008, Szydlowska and Tymianski 
2010). Among the Ca2+ permeable channels contributing to the initial free radical production are 
NMDAR, VGCC, and Transient Receptor Potential Melastatin (TRPM) 2 and 7 (Szydlowska and 
Tymianski 2010). TRPs are a family of diverse calcium permeable channels that respond to 
stress, changes in pH, or temperature (McHugh, Flemming et al. 2003, Miller 2004, Sun, 
Jackson et al. 2009). The focus of this dissertation is the TRPM2 channel, shown to be critical in 
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oxidative stress and cerebral ischemia (Nakayama, Vest et al. 2013, Shimizu, Macey et al. 
2013).   
Transient Receptor Potential Melastatin 2 channel (TRPM2) 
TRP channels are a broad family of cation-permeable channels composed of six 
transmembrane domains, a pore region located between segments five and six (S5-S6), and 
both N- and C-terminus facing the intracellular milieu (Perraud, Fleig et al. 2001, Sumoza-
Toledo and Penner 2011). TRPM1-8 family members are characterized by a melastatin 
homology domain in the N-terminus; three family members are C-terminus chanzymes with 
unique regulatory mechanisms (Montell 2005). The focus of this dissertation is on TRPM2 
channels, also known as LTRPC2 or TRPC7 (Nagamine, Kudoh et al. 1998, Perraud, Fleig et 
al. 2001), a member of the subfamily of melastatin channels. TRPM2 is ubiquitously expressed 
in the peripheral and central nervous system, with the highest expression found in brain, 
immune cells, and pancreas (Fonfria, Murdock et al. 2006). TRPM2 features four melastatin 
homology domains in the N-terminus followed by a CaM IQ-motif that modulates channel 
activation via Ca2+ signaling. Also, TRPM2 contains a TRP conserved domain (LPPPFI), and 
other regulatory regions within the C-terminus (Nagamine, Kudoh et al. 1998, Perraud, Fleig et 
al. 2001) (Figure 1.2).  
The C-terminus contains a Nudix (NUDT9-H) domain homologous to NUDT9 
mitochondrial hydrolase involved in pyrophosphate breakdown hijacked for adenosine 
diphosphate ribose (ADPR) binding and activation of TRPM2 channels (Kuhn and Luckhoff 
2004, Perraud, Takanishi et al. 2005). Activation by ADPR leads to long periods of TRPM2 
channel opening ranging from milliseconds to seconds (Herson, Dulock et al. 1997). The  
current-voltage (I-V) relationship for TRPM2 is linear, having an Erev=0mV; the channel 
conductance is ~60pS. Long periods of opening are a significant source of Ca2+ despite higher 
channel permeability to Na+=K+ > Ca2+; associated to cell death and other physiological 
functions (Sano, Inamura et al. 2001, Hara, Wakamori et al. 2002). Cryo-electron microscopy 
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(cryo-EM) structure of TRPM2 revealed that the N- and C-termini interact with each other and 
have intra- and inter-subunit interactions in the closed state. Moreover, ADPR primes the 
channel and induces a conformational change favoring an open-channel state that is enhanced 
with Ca2+ binding (Fliegert, Holzer et al. 2018, Huang, Winkler et al. 2018, Wang, Fu et al. 
2018).  
The sources of ADPR synthesis are critical in determining upstream mechanisms of 
activation in cellular pathways, especially in pathophysiological conditions such as cerebral 
ischemia, in which high levels of ADPR are the main agonist of TRPM2 (Fonfria, Mattei et al. 
2006, Shimizu, Macey et al. 2013). Among ADPR upstream sources are glycohydrolases such 
as CD38 and CD157, mitochondrial nicotinamide adenine dinucleotide (NAD) nucleosidases, 
which hydrolyze NAD+ or cyclic ADPR into free ADPR (Partida-Sanchez, Gasser et al. 2007, 
Ma, Nie et al. 2015). Other enzymes such as poly-ADPR-polymerases (PARP) and poly-ADPR-
glycohydrolases (PARG) produce free ADPR during DNA damage response, and sirtuins (SIRT) 
2/3 which produce ADPR precursors (Grubisha, Rafty et al. 2006, Buelow, Song et al. 2008, 
Shimizu, Quillinan et al. 2016).  
TRPM2 downstream signaling is Ca2+ dependent with a variety of functional roles in 
multiple cell-types and organs (Inamura, Sano et al. 2003, Kraft, Grimm et al. 2004, Partida-
Sanchez, Gasser et al. 2007, Lange, Yamamoto et al. 2009, Chung, Freestone et al. 2011, Xie, 
Belrose et al. 2011, Gattkowski, Johnsen et al. 2019). The most studied role of TRPM2 in 
pathophysiology involves cell death (Li and Jiang 2019). In cerebral ischemia, TRPM2 activation 
is occurs via biochemical generation of ADPR and oxidative stress serving as a positive 
feedback for ADPR generation along with increased Ca2+ levels (Perraud, Takanishi et al. 2005, 
Olah, Jackson et al. 2009, Shimizu, Macey et al. 2013). PARP-1 and SIRT are upstream of 
TRPM2 in ischemia models (McCullough, Zeng et al. 2005, Shimizu, Macey et al. 2013, Ma, Nie 
et al. 2015, Shimizu, Quillinan et al. 2016). More recently, TRPM2 is linked to tumor pro-survival 
signals, depression, regulation of social interactions, and temperature responses (Tan and 
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McNaughton 2016, Almasi, Kennedy et al. 2018, Andoh, Nishitani et al. 2019, Ko, Wang et al. 
2019). TRPM2 downstream signaling in neurons includes calcineurin (CaN) and glycogen 
synthase kinase 3 (GSK3) modulating NMDAR signaling in hippocampal neurons (Olah, 
Jackson et al. 2009, Xie, Belrose et al. 2011, Alim, Teves et al. 2013). Therefore, increasing 
evidence suggests that TRPM2 plays crucial roles in physiological and pathophysiological 
states, requiring specific and potent antagonists to determine cell-type specific functions.  
TRPM2 antagonists include endogenous adenosine mono-phosphate (AMP), the non-
steroidal anti-inflammatory flufenamic acid (FFA), N-(p-amylcinnamoyl) anthranilic acid (ACA), 
2-aminoethoxy-dephenyl borate (2-APB), the antifungal clotrimazole (CTZ), among other 
inhibitors (Hill, McNulty et al. 2004, Chen, Zeng et al. 2012, Moreau, Kirchberger et al. 2013, 
Starkus, Poerzgen et al. 2017, Zhang, Liu et al. 2018, Baszczynski, Watt et al. 2019, 
Fourgeaud, Dvorak et al. 2019). These inhibitors have low potency or selectivity for TRPM2 
channels from which CTZ and JNJ-28583113 are the inhibitors with higher specificity. Our lab 
has designed an inhibitor of TRPM2, tatM2NX, which specifically mimics the ADPR binding site 
and inhibits human TRPM2 channels in vitro (Shimizu, Dietz et al. 2016). In this body of work, I 
used tatM2NX as a tool to understand TRPM2 activity following cerebral ischemia. 
Calcineurin (CaN) 
CaN, also known as protein phosphatase 2B, is a serine/threonine Ca2+-CaM dependent 
phosphatase highly expressed in hippocampus, cortex, striatum, and cerebellum (Asai, Qiu et 
al. 1999). In neurons, CaN is an important regulator of local synaptic activity via anchoring by A-
kinase anchoring protein (AKAP79/150) to induce Ca2+-dependent inactivation of its targets 
(Coghlan, Perrino et al. 1995, Oliveria, Dittmer et al. 2012). CaN is composed of two subunits; 
the catalytic subunit A and regulatory subunit B. The catalytic subunit A has α, β, and γ isoforms 
while the regulatory subunit B has B1 and B2 isoforms (Aramburu, Rao et al. 2000). The 
catalytic subunit A contains the catalytic site and the regulatory region that encompasses the 
catalytic binding domain, the CaM binding domain, and the auto-inhibitory domain. The 
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regulatory subunit B contains two low-affinity and two-high affinity Ca2+ binding sites accounting 
for basal/structural and activity-dependent CaN functions. Ca2+ binding to CaN subunit B and 
CaM causes displacement of the auto-inhibitory subunit to expose the catalytic domain 
(Connolly, Quasi-Woode et al. 2018). This feature allows for CaN activity during subtle changes 
in cellular activity determining the variety of signals (Connolly, Quasi-Woode et al. 2018, 
Tarasova, Gaydukov et al. 2018).  
In neurons, CaN activation during Ca2+ oscillations regulates pre- and post-synaptic 
activity, homeostasis, and gene expression (Klee, Crouch et al. 1979, Mukherjee and Soto 
2011). Downstream signals involve cAMP response element-binding protein (CREB)-dependent 
gene expression, nuclear factor of activated T cells (NFAT) translocation to the nucleus, 
interactions with NMDAR and GSK3, and activation of cytochrome c/caspase-3 (Lieberman and 
Mody 1994, Tong, Shepherd et al. 1995, Asai, Qiu et al. 1999, Mansuy 2003, Kim, Lee et al. 
2009, Li, Pink et al. 2012). CaN can also act presynaptically to regulate endocytosis 
(Baumgartel and Mansuy 2012). Studies identifying CaN function use competitive 
pharmacological antagonists cyclosporin A and FK506 to block binding to its targets (Liu, 
Farmer et al. 1991).  
Excessive Ca2+ influx activates CaN in neurons and glia leading to neuronal dysfunction 
and cell death (Mukherjee and Soto 2011). CaN remains chronically active due to oxidative 
stress such as in cerebral ischemia (Onodera, Yamasaki et al. 1995, Erin, Lehman et al. 2003). 
In addition, chronic CaN activity in Alzheimer’s disease (AD) dephosphorylates AMPAR at 
synapses leading to receptor internalization and LTP inhibition (Zhao, Santini et al. 2010). 
Moreover, CaN is found in NMDAR complexes at post-synaptic density and interacts with GSK3 
in vitro (Husi, Ward et al. 2000, Kim, Lee et al. 2009). Therefore, Ca2+-dependent TRPM2 





Glycogen synthase kinase-3 (GSK3)    
GSK3 is an abundant serine/threonine (Ser/Thr) kinase with α and β isoforms highly 
expressed in the brain with the β isoform being predominant in adulthood and critical for major 
neuronal activity (Woodgett 1990, Salcedo-Tello, Ortiz-Matamoros et al. 2011). GSK3 is found 
in hippocampus, cortex, and cerebellum (Yao, Shaw et al. 2002). During development, GSK3 is 
critical for neuronal growth and genetic ablation leads to deficits in synapse formation (Hur and 
Zhou 2010, Tyagarajan, Ghosh et al. 2011, Rui, Myers et al. 2013). In adulthood, GSK3 
substrates vary depending on subcellular localization, protein-protein interactions, substrate 
specificity, and cleavage (Otto, Eichenbaum et al. 1991, Xu, Kim et al. 2009, Reis, Chen et al. 
2015, Patel and Woodgett 2017). In synaptic plasticity, GSK3β activity is inhibited by LTP 
induction while overexpression impairs the induction of LTP in CA1 hippocampal neurons 
(Hooper, Markevich et al. 2007, Peineau, Taghibiglou et al. 2007), suggesting that abnormal 
GSK3β activation in pathophysiology is potentially detrimental for synaptic function. 
GSK3 is active under resting conditions via tyrosine (Tyr216/279) phosphorylation 
(Hughes, Nikolakaki et al. 1993) and becomes inactivate through serine (Ser9/21) 
phosphorylation (β and α, respectively) (Sutherland, Leighton et al. 1993). Therefore, de-
phosphorylation at Ser9/21 is the most commonly used readout for activation (Wang, Fiol et al. 
1994). GSK3 undergoes additional regulatory processes via auto-inhibition through N-terminal 
phosphorylation that serves as a pseudo-substrate (Dajani, Fraser et al. 2001). Among GSK3 
upstream kinases phosphorylating Ser9/21 (inactivating) are protein kinase B (AKT), protein 
kinase A (PKA), protein kinase C (PKC), ribosomal protein S6 kinase (p70S6K) and (p90RSK), 
while protein phosphatases 1 (PP1), 2A (PP2A), and CaN activate GSK3 via Ser9/21 de-
phosphorylation (Kim, Lee et al. 2009, Salcedo-Tello, Ortiz-Matamoros et al. 2011).  
Reciprocal CaN and GSK3 signaling occurs in neurons via direct and indirect 
mechanisms. NMDAR-dependent activation of CaN can also de-phosphorylate GSK3β (Ser9) 
via inhibitor-1 (I-1) and PP1 (Mulkey, Herron et al. 1993, Mulkey, Endo et al. 1994, Szatmari, 
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Habas et al. 2005). Conversely, GSK3 can also regulate CaN through phosphorylation of the 
regulator of CaN (RCAN) leading to changes in activity of downstream targets (Graef, 
Mermelstein et al. 1999, Hilioti, Gallagher et al. 2004, Takeo, Swanson et al. 2012). GSK3 can 
phosphorylate upstream inhibitory signals as a feedback mechanism to perpetuate its activation, 
which is particularly important in pathological conditions where GSK3 abnormal activity can lead 
to cognitive deficits (King, Pardo et al. 2014).  
In AD human brains, GSK3 expression and activity increases (Pei, Tanaka et al. 1997, 
Leroy, Yilmaz et al. 2007). In rodents, amyloid β increases GSK3β activity via phosphorylation 
of Tyr216 resulting in cognitive impairment (Terwel, Muyllaert et al. 2008), and leads to 
decreased NMDAR surface expression (Zhu, Wang et al. 2007, Deng, Xiong et al. 2014). De-
phosphorylation of GSK3 days after transient ischemia indicates increased enzymatic activity 
(Chen, Ahn et al. 2017) and GSK3 inhibition is neuroprotective in vitro and in vivo (Kelly, Zhao 
et al. 2004, Li, Li et al. 2010). Moreover, TRPM2 is associated with changes in NMDAR subunit 
expression and GSK3 phosphorylation thereby modulating neuronal sensitivity to cell death 
(Alim, Teves et al. 2013). Overall, these suggest that GSK3 can regulate NMDAR-dependent 
synaptic plasticity after cerebral ischemia through TRPM2 channels. 
Rationale 
It is well appreciated that neuronal injury due to cerebral ischemia activates Ca2+ 
permeable ion channels such as Transient Receptor Potential Melastatin 2 (TRPM2) along with 
ionic imbalance, mitochondrial dysfunction, and oxidative/nitrosative stress as a result of 
insufficient oxygen and glucose. Among the known functions of TRPM2 is the Ca2+-dependent 
cell death signaling in microglia. Nonetheless, the mechanism of TRPM2 function in neuronal 
pathophysiology remains understudied.  
We have previously reported that LTP is impaired up to 30 days after global ischemia. 
Because TRPM2 inhibition is neuroprotective after cerebral ischemia, we sought to determine 
whether TRPM2 inhibition also recovers LTP function in CA1 hippocampal neurons. In Chapter 
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II, we developed and characterized a novel peptide tatM2NX to target the ADPR binding site on 
TRPM2 with the purpose of studying this ion channel following cerebral ischemia. In Chapter III 
we show that LTP impairment is reversed upon TRPM2 inhibition at 7 and 30 days after 
cerebral ischemia, suggesting that TRPM2 activity plays a role in persistent functional 
impairment in the surviving CA1 neuronal network. Our goal with this study is to provide a 
potential therapeutic strategy to improve functional outcomes in patients presenting memory 
and cognitive deficits by targeting TRPM2 channels and/or other proteins that occlude LTP. 
Research questions 
Is tatM2NX an antagonist of TRPM2 channels? 
Is sustained TRPM2 activity contributing to synaptic plasticity impairment? 
Specific aims 
1) Characterize and optimize tatm2nx as a trpm2 channel antagonis and pharmacological 
tool to study cellular function (Figure 1.3). 
2) Determine modifications to trpm2 activity leading to synaptic plasticity impairment 
following global cerebral ischemia (Figure 1.3). 
Hypotheses 
Modifications to TRPM2 activity, resulting from oxidative stress after cerebral ischemia, 
lead to sustained influx of Ca2+ and activation of Ca2+ dependent signaling through CaN and 
GSK3 to subsequently affect NMDAR-dependent plasticity. I expect that inhibition of TRPM2 
channels will dampen Ca2+ signals regulating NMDAR activity required for synaptic plasticity in 






Figure 1.1 The hippocampal structure. The hippocampal structure is subdivided into 
dentate gyrus (DG), CA3, CA2, CA1, and subiculum. The entorhinal cortex sends inputs to 
the hippocampus, which outputs from CA1 and subiculum. During field excitatory post-
synaptic potential (fEPSPs) recordings, electrodes are placed in CA1 hippocampal 
neurons (recording electrode) to monitor responses to a high-frequency stimulation from 
Schaffer collaterals (Sch) on CA3 neurons (stimulating electrode). Image created by 




















Figure 1.2 Schematic of TRPM2 channel structure. TRPM2 contains six 
transmembrane domains (S1-S6), the pore, and intracellular N- and C- termini. The 
N-terminus has four TRPM homology domains (MH1-4). The C-terminus has a 
TRP box, a coil-coiled domain and the NUDT9-H domain (ADPR binding site). 




















Figure 1.3 Mechanism of LTP impairment following cerebral ischemia. During an 
ischemic insult, surviving hippocampal neurons display compromised physiology. 
This is due in part because cerebral ischemia either increases the number of TRPM2 
channels in the membrane of increases ADPR concentration thereby increasing 
TRPM2 activity. This leads to impairment of LTP days after cerebral ischemia. Aim 1: 
Characterize the TPRM2 inhibitor tatM2NX; Aim 2: Identify how TRPM2 contributes 




2TATM2NX IS A POTENT TRPM2 ANTAGONIST 
Introduction and review of the literature 
  TRPM2 is a non-selective cation channel from the TRP family. At physiological 
membrane potentials, activation of TRPM2 results in influx of Na+ and Ca2+ into the cell. TRPM2 
forms tetramers composed of six transmembrane domains with the N- and C-termini facing the 
intracellular milieu. The C-terminus contains a unique NUDT9-H domain required for ADPR 
binding and activation, absent in other TRP family members (Tong, Zhang et al. 2006, Hantute-
Ghesquier, Haustrate et al. 2018). TRPM2 was initially described as a channel/enzyme 
(chanzyme) due to the presence of the NUDT9-H domain; however, subsequent work has 
demonstrated that the C-terminal NUDT9-H domain of TRPM2 lacks enzymatic activity 
(Perraud, Shen et al. 2003, Iordanov, Mihalyi et al. 2016).  The NUDT9-H domain of TRPM2 is 
essential for intra- and interface interactions that regulate TRPM2 channel activation by ADPR 
(Huang, Winkler et al. 2018, Wang, Fu et al. 2018). Intracellular Ca2+ serves as a co-agonist, 
modulating channel activity in the presence of ADPR (Herson, Dulock et al. 1997, Herson, Lee 
et al. 1999, Perraud, Fleig et al. 2001, Inamura, Sano et al. 2003, McHugh, Flemming et al. 
2003, Kuhn and Luckhoff 2004, Heiner, Eisfeld et al. 2006, Olah, Jackson et al. 2009, Toth, 
Iordanov et al. 2015, Fliegert, Bauche et al. 2017, Fliegert, Watt et al. 2017, Yu, Xue et al. 
2017). Consistent with these physiological observations, the recently solved human TRPM2 
channel structure indicates an ADPR binding site in the C-terminus that appears to interact with 
the N-terminus upon opening and leads to structural changes in a Ca2+-dependent ‘primed’ state 
(Huang, Winkler et al. 2018, Wang, Fu et al. 2018). 
                                                             
2 Portions of this chapter are under review in Molecular Pharmacology. Citation: Cruz-Torres, I., Backos, 
D.B., Herson, P.S. Molecular Pharmacology (2019). 
  Patent pending. 
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  TRPM2 channels have been implicated in several physiological and pathophysiological 
conditions in multiple organs (Inamura, Sano et al. 2003, Smith, Herson et al. 2003, Fonfria, 
Marshall et al. 2004, Kraft, Grimm et al. 2004, Fonfria, Murdock et al. 2006, Lange, Yamamoto 
et al. 2009, Haraguchi, Kawamoto et al. 2012, Verma, Quillinan et al. 2012, Alim, Teves et al. 
2013, Shimizu, Macey et al. 2013, Gelderblom, Melzer et al. 2014, Hoffman, Miller et al. 2015, 
Jang, Lee et al. 2015, Park, Chun et al. 2016, Tan and McNaughton 2016, Andoh, Nishitani et 
al. 2019, Li and Jiang 2019). TRPM2 channels are highly expressed in the brain, found in 
neurons and microglia in the cortex, hippocampus, striatum, brainstem and others (Fonfria, 
Murdock et al. 2006, Olah, Jackson et al. 2009, Chung, Freestone et al. 2011). TRPM2 
channels are activated following oxidative stress, and the most well-characterized role for these 
channels is a cell death mediator following oxidative stress, due to excessive Ca2+ influx and 
consequent cell death (Fonfria, Marshall et al. 2004, Perraud, Takanishi et al. 2005, Bai and 
Lipski 2010). However, the lack of specific TRPM2 channel antagonists has hindered the 
research regarding the role of TRPM2 channels in brain function, with most data coming from 
cell culture experiments or global TRPM2 channel genetic ablation in mice. Thus far, most 
described TRPM2 pharmacological inhibitors are not specific to TRPM2 channels, including  
antifungals, FFA, fenamate non-steroidal anti-inflammatories, 2-aminoethoxydiphenyl borate (2-
APB), and natural compounds with moderate to high potency (Hill, McNulty et al. 2004, Chen, 
Zeng et al. 2012, Starkus, Poerzgen et al. 2017, Zhang, Liu et al. 2018). The TRPM2 inhibitor, 
JNJ-28583113, is a recently described inhibitor that appears promising, with nanomolar potency 
when applied to the extracellular surface of TRPM2 channels, however is limited by difficulties 
reaching the brain (Fourgeaud, Dvorak et al. 2019). In contrast, we recently reported that the 
inhibitor, tatM2NX, reduces ischemic injury when administered following focal cerebral ischemia 
(Shimizu et al 2016) and global cerebral ischemia (Dietz, Cruz-Torres et al. 2019) in vivo, 
providing evidence for clinical benefit. Therefore, the aim of this study was to characterize the 
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TRPM2 channel inhibitor tatM2NX, designed to interact with the ADPR binding site on the 
NUT9-H domain. 
In this SAR study, we show that tatM2NX is an antagonist of human TRPM2 channels 
using whole-cell patch clamp and Ca2+ in HEK293 cells. Mutagenesis of tatM2NX reveals that 
the mechanism of action results from tatM2NX C-terminal interactions with TRPM2. Ultimately, 
tatM2NX is a potent pharmacological tool to disentangle TRPM2 function in cellular physiology 
and neurological diseases. 
Results 
Modeling for tatM2NX antagonism on TRPM2 
We recently showed the peptide tatM2NX is a TRPM2 antagonist with selective 
neuroprotective effects in a mouse model of focal ischemia (stroke) (Shimizu, Dietz et al. 2016) 
and global ischemia (CA/CPR) (Dietz, Cruz-Torres et al. 2019). To characterize the mechanism 
of TRPM2 inhibition by tatM2NX, we performed molecular modeling (MD) to allow prediction of 
tatM2NX interaction/inhibition of activity and potential key residues responsible for efficacy. Ab 
initio prediction of the secondary and tertiary structure of the parent tatM2NX inhibitor peptide 
was predicted to adopt a single, alpha helical structure that remained stable during MD-based 
refinement and analysis (Figure 2.1A, Table 2.1).  
Protein-peptide complex prediction for tatM2NX indicated that the top scoring cluster for 
the peptide involved direct interaction with the human ADPR binding site (Figure 2.1B), which 
suggests occlusion of this site and the resulting inhibition of ADPR binding as a potential 
mechanism for the observed functional inhibition of TRPM2 in vitro. To test the stability of the 
predicted complex, we performed a 5ns MD-based simulation in the presence of an explicit 
solvent. The TRPM2-tatM2NX complex remained stable throughout the simulation and 
appeared to settle further into the ADPR binding site and enhance the number of favorable 
interactions between tatM2NX and TRPM2 compared to the initial predicted complexes (Figure 
2.1C, Table 2.2). At the end of the MD simulation period, tatM2NX made numerous favorable 
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intermolecular interactions, including salt-bridges with arginine (Arg) 1280 and Arg1433 as well 
as an extensive network of intermolecular hydrogen bonds and hydrophobic interactions (Table 
2.2). TatM2NX also appeared to form a wedge-like conformation, with the C-terminus portion 
interacting with the ADPR binding site and the Tat-HIV tag (N-terminus) interacting with the 
opposite side of the TRPM2 monomer (Figure 2.1C, right). 
Human TRPM2 channels are expressed and functional in HEK293 cells  
We measured TRPM2 protein expression and localization in HEK293 cells. Human 
TRPM2 (N-terminus FLAG tag) expressed after doxycycline treatment (16-18h) (Figure 2.2A, 
B). To validate human TRPM2 expression, we performed whole cell patch-clamp experiments 
with ADPR present in the pipette solution to stimulate TPRM2-mediated currents. We found that 
human TRPM2 exhibited large initial current density (ADPRi, 184.4 ± 28.50 pA/pF, n=5) 
exclusively under doxycycline treatment (Figure 2.2C, Figure 2.3A). We observed significant 
rundown of TRPM2 initial current density (ADPRf, 86.45 ± 20.87 pA/pF, n=5; p<0.05), which 
reached steady-state levels after 2-3min, as previously described (Toth and Csanady 2012) 
(Figure 2.2C). Therefore, subsequent experimental analysis was performed using the steady 
state current density at 3min as the active TRPM2 current (ADPRf). Multiple control experiments 
were performed to confirm the ADPR-induced current in HEK293 cells were carried by TRPM2 
channels. Importantly, the TRPM2 channel pore-blocker Clotrimazole (20µM CTZ) abolished 
ADPR currents (6.35 ± 1.639 pA/pF, n=10; p<0.05) (Figure 2.2C). Also, un-induced (no-
doxycycline treatment) cells lacked TRPM2 expression or activity (0.58 ± 0.31 pA/pF, n=6, 
p˃0.05) (Figure 2.2A, D). These results validate TRPM2 expression and function in 
doxycycline-treated HEK293 cells.  
TatM2NX is a potent TRPM2 antagonist 
To characterize tatM2NX as an antagonist we performed a dose-response study. To 
achieve a known concentration of ligand and antagonist within the cell, we used whole-cell 
patch clamp with ADPR (100µM) and tatM2NX added to the internal solution (pipette) allowing 
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free dialysis into the cell once whole cell access was obtained. Our results show a 
concentration-dependent decrease in TRPM2 current density. We observed approximately 75% 
inhibition of initial TRPM2 current at 0.5µM tatM2NX (37.82 ± 23.79 pA/pF, n=5; p˂0.05), and 
approximately 90% inhibition at 2µM (10.27 ± 3.60 pA/pF, n=7; p˂0.05), 5µM (7.76 ± 2.85  
pA/pF, n=5; p˂0.05), and 10µM tatM2NX (13.17 ± 6.68, n=4; p˂0.05) (Figure 2.3A, B). No 
differences were observed for 0.15µM (121.6 ± 31.33 pA/pF, p>0.05), 0.3µM (118.0 ± 22.66 
pA/pF, p>0.05) tatM2NX compared to 0.05µM (142.2 ± 34.32 pA/pF, n=7) (Figure 2.3B). The 
ineffective concentration of 0.05µM tatM2NX was similar to ADPR alone (ADPRf, 86.45 ± 20.87 
pA/pF, n=5) (Figure 2.2E). A non-linear regression method (log inhibitor concentration versus 
normalized response) of the tatM2NX dose-response estimated a potency (IC50) of 3.96e-007 ± 
0.05868 (396nM) (Figure 2.3C). These results suggest that tatM2NX is a potent antagonist of 
TRPM2 currents in the presence of ADPR.  
To validate tatM2NX binding to TRPM2 as predicted in our MD, we performed co-
immunoprecipitation using the N-terminal biotin-tag on tatM2NX. To do this, we extracted whole-
cell protein lysates from HEK293 cells and incubated protein lysates (500µg) with biotinylated-
tatM2NX (20µg). The peptide biotin-tatM2NX formed a complex with TRPM2 when co-
immunoprecipitated using agarose-conjugated streptavidin (Figure 2.4A). This binding 
interaction is specific to HEK293 cells expressing TRPM2 (+) and absent in un-induced cells (-). 
These results indicate that tatM2NX directly interacts with TRPM2.   
We next assessed the ability of tatM2NX to inhibit TRPM2-mediated de-phosphorylation 
of GSK-3β (activation), as this signaling pathway has recently been shown in cell culture 
(Fourgeaud, Dvorak et al. 2019) and brain slices (Dietz, Cruz-Torres et al. 2019). TRPM2 
stimulation with H2O2 (250µM) activates GSK3β (de-phosphorylation) in HEK293 cells compared 
to untreated cells (Con) (Figure 2.4B). Pre-incubation with tatM2NX (2µM) for 2-4h prevents 
GSK3β activation indicating that tatM2NX inhibits TRPM2-mediated GSK3β signaling (Figure 
2.4B).  To determine whether tatM2NX acts as a competitive antagonist for human TRPM2 
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channels, we tested the antagonistic capacity of 2µM tatM2NX in the presence of 500µM ADPR. 
In these ligand saturating conditions, ADPRf was not significant (117 ± 5.26 pA/pF, p>0.05, n=4) 
compared to ADPRi current density (173.1 ± 22.61 pA/pF, n=4) (Figure 2.4C). Interestingly, 
2µM tatM2NX failed to inhibit (89.22 ± 21.11 pA/pF, n=4; p>0.05) ADPRf current density 
indicating that higher concentrations of ADPR can prevent tatM2NX antagonism (Figure 2.4C). 
These results indicate that tatM2NX is a competitive antagonist of TRPM2 and serves to 
validate the results of our MD simulations.  
TatM2NX C-terminus is sufficient to antagonize TRPM2 in cells 
Based on the initial MD of tatM2NX in complex with TRPM2, we identified two bulky 
hydrophobic residues, tryptophan in position 33 and valine in position 34 (W33, V34) within the 
C-terminus that remained buried within the ADPR binding site throughout the MD simulation. 
We hypothesized that mutating these two residues would potentially abrogate the binding of 
tatM2NX to the ADPR binding site. MD of tatM2NX with W33A and V34A mutations to W33V34 
(tat-WVAA) indicated a loss of interaction with the ADPR binding site in any of the top 3 scoring 
interaction clusters (Figure 2.5A) nor did we observe any substantive interactions with this site 
in any of the lower scoring results (data not shown). We performed additional computational 
simulations to assess the capacity of a truncated form of tatM2NX (tat Cterm; containing the last 
23 amino acids) to preserve these interactions with the ADPR binding site. The peptide tat 
Cterm interacts with the ADPR binding site similarly to the parent peptide tatM2NX (Figure 
2.5A, C). This suggested that the C-terminus of tatM2NX was sufficient to interact with the 
ADPR binding site and would likely recapitulate the inhibitory effects of the parent peptide 
tatM2NX on TRPM2. Similar to tatM2NX, the tat Cterm peptide was predicted to maintain and 
enhance interactions with the ADPR binding site over the simulation period (Figure 2.5B, C, 
Table 2.3). In contrast, the interactions of the tatWV-AA peptide did not appear stable and had 
substantial dissociation from TRPM2 (Figure 2.5B, D) suggesting that tatWV-AA lacks 
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physiologically relevant interactions with TRPM2. The overall structure of both tat Cterm and 
tatWV-AA peptides were highly similar in terms of secondary/tertiary structure (Figure 2.5B). 
Our MD predicted stable interactions of tat Cterm and that mutating W33V34 to AA 
would result in a loss of interaction with the ADPR binding site. To validate the MD results, we 
performed cell-based functional assays using electrophysiology and Ca2+ imaging. In whole-cell 
patch clamp, the peptide tat-WVAA contained within the C-terminus (Table 2.1) lacks 
antagonism on TRPM2 (116.3 ± 27.31 pA/pF, n=6; p>0.05) compared to ADPRf, indicating that 
either/both residues are required to confer antagonism (Figure 2.6A). Because the tat Cterm 
peptide clustered by the ADPR binding site, we tested N- and C-termini truncated peptides (23 
amino acids each) to determine the extent of antagonism by these truncated forms of tatM2NX 
(Table 2.1). In whole-cell patch clamp experiments, tat Cterm displayed antagonism (15.56 ± 
3.07 pA/pF, n=6; p˂0.05) compared to ADPRf (89.39 ± 14.48 pA/pF, n=5) (Figure 2.6A). The N-
terminus truncation (tat Nterm) did not inhibit TRPM2 (141.2 ± 15.73 pA/pF, n=4; p>0.05) 
compared to ADPRf (Figure 2.6A). These results suggest that tatM2NX C-terminus is sufficient 
to inhibit TRPM2 while the N-terminus alone lacks antagonistic effect. Also, these confirms that 
the tat-HIV tag, and not the N-terminus sequence, is responsible for direct interactions with 
TRPM2 and requires the C-terminus residues W33V34 in proximity to the ADPR binding site. 
Lastly, all ADPRi currents were similar in the presence of peptides compared to control (Figure 
2.7A).  
To verify that tatM2NX was cell permeable, we incubated biotin-tatM2NX with HEK293 
cells for 1h, followed by immunocytochemistry and N-terminal tagged biotin-tatM2NX in HEK293 
cells with N-terminal tagged (cytosolic) FLAG-TRPM2 (Figure 2.2B). To test whether these 
peptides show antagonistic effects when applied extracellularly, we measured Ca2+ in HEK293 
cells in response to H2O2 stimulation and analyzed the area under curve (AUC: F/F0 x min). 
H2O2 stimulated Ca2+ influx through TRPM2 in control group (77,441 ± 4,779 F/F0 x min; n=54) 
as previously described (Herson, Lee et al. 1999, Kraft, Grimm et al. 2004, Olah, Jackson et al. 
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2009, Shimizu, Dietz et al. 2016) (Figure 2.6B, C). TatM2NX and tat Cterm significantly 
decreased Ca2+ fluorescence (F/F0) after 20min (47,904 ± 4,510 F/F0 x min; n=48, p˂0.05; and 
50,600 ± 3,800 F/F0 x min; n=49, p˂0.05, respectively) (Figure 2.6B, C, D). However, tat Nterm 
(67,851 ± 4,883 F/F0 x min; n=48, p>0.05) had no effect on Ca2+ fluorescence activated by H2O2 
(Figure 2.6C, D). On the other hand, Ca2+ fluorescence with tat-WVAA was higher than H2O2 
(102,979 ± 6,591 F/F0 x min; n=53, p˂0.05) and the positive control CTZ inhibited Ca2+ 
fluorescence as expected (31,910 ± 2,176 F/F0 x min; n=25, p<0.05) (Figure 2.6D). All cellular 
responses in the presence of peptides had similar fluorescent kinetics as H2O2 stimulation alone 
(H2O2, 17.55 ± 0.38 min; tatM2NX, 16.83 ± 0.46 min; tat Cterm, 17.83 ± 0.45 min; tat Nterm, 
18.37 ± 0.34; tat-WVAA, 17.13 ± 0.51 min) (Figure 2.7B). These data suggest that tat Cterm 
inhibits TRPM2 activity in cells at similar levels as tatM2NX and residues W33V34 are essential 
for antagonism.  
Discussion 
In this study, we evaluated the pharmacological properties of tatM2NX on TRPM2 
channels and found evidence of potent inhibition; with an IC50 of approximately 396nM. 
Furthermore, we identified two residues within tatM2NX C-terminus, W33 and V34, necessary 
for antagonism. Our MD of TRPM2 (in the closed channel state) and tatM2NX show direct 
interactions of tatM2NX with the ADPR binding site. These results are consistent with co-
immunoprecipitation of tatM2NX and reduced inhibition in the presence of excess ADPR. 
Recently, cryoEM structures validated previous TRPM2 mutagenesis studies indicating that the 
ADPR binding site is contained within NUDT9-H (Shen, Perraud et al. 2003, Kuhn and Luckhoff 
2004, Yu, Xue et al. 2017, Huang, Winkler et al. 2018, Wang, Fu et al. 2018). TRPM2 
undergoes conformational changes in the C-terminus NUDT9-H domain priming an open-
channel state upon ADPR binding. Our results support that tatM2NX disrupts the ability of 
ADPR to open TRPM2 channels. This is the first characterization, to our knowledge, of a 
peptide inhibitor targeting TRPM2 with in vivo applications. 
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The peptide tatM2NX was predicted to both directly interact with the human ADPR 
binding site and to remain wedged in place via the interactions of the tat-HIV (permeability 
sequence) outside of the ADPR site. Activation of TRPM2 involves extensive conformational 
changes to the cytosolic N- and C-terminal regions of TRPM2 that bring the globular domains in 
closer proximity to one another (Huang, Winkler et al. 2018, Wang, Fu et al. 2018). The 
modeling results suggest that, in addition to occluding the ADPR binding site, tatM2NX may also 
directly impede the molecular mechanics of activation by blocking or impairing these 
conformational changes. 
The interactions of tat Cterm with the ADPR binding site were stable and the peptide 
itself moved further into the ADPR binding site over the simulation period. These results suggest 
that the C-terminus hydrophobic interactions with the ADPR binding site are sufficient to 
maintain the TRPM2-tat Cterm interactions. Interestingly, the best predicted complexes for the 
active inhibitory peptides involved binding at the human ADPR site with extensive stable 
interactions (Table 2.2, 2.3). Future mutagenesis studies may reveal which interactions are 
required for inhibition. Other top ranked complexes for both tatM2NX and tat Cterm peptides 
involved interaction with the region corresponding to the ADPR binding site in zebrafish TRPM2 
(Fliegert, Holzer et al. 2018, Huang, Winkler et al. 2018) suggesting that these peptides may 
also have inhibitory effects against the activity of zebrafish TRPM2. Also, we have shown 
efficacy in mouse models of brain ischemia (Shimizu, Dietz et al. 2016, Dietz, Cruz-Torres et al. 
2019) , therefore this tool has potential use in multiple systems and species. 
Isolating TRPM2 function in physiology and pathophysiology is critical to understand 
signaling downstream of TRPM2 channel activation. Previous studies used non-specific 
pharmacological inhibitors to show the involvement of TRPM2 function increasing oxidative 
stress signaling (Fonfria, Marshall et al. 2004, Perraud, Takanishi et al. 2005). More recently, 
total genetic ablation approaches in rodents associate TRPM2 with mood disorders, social 
interactions, temperature control, and Alzheimer’s disease, implicating increased TRPM2 
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channel activity in various neurological diseases across many brain regions (Jang, Lee et al. 
2015, Ostapchenko, Chen et al. 2015, Tan and McNaughton 2016, Alawieyah Syed Mortadza, 
Sim et al. 2018, Andoh, Nishitani et al. 2019). Therefore, pharmacological targeting of this 
channel has the potential to provide clinical benefit in several neurological disorders. However, 
there are is a lack of inhibitors that would be amenable to clinical use. We believe tatM2NX 
represents the most promising TRPM2 pharmacological inhibitor available to date. A single 
dose of tatM2NX effectively crosses the blood-brain barrier while providing TRPM2 specific 
neuroprotection in stroke and cardiac arrest animals, setting precedence for the use of tatM2NX 
in vivo (Shimizu, Dietz et al. 2016, Dietz, Cruz-Torres et al. 2019). These studies demonstrate 
the ability of tatM2NX to cross the BBB and impact brain injury, consistent with several previous 
studies showing tat-conjugated proteins crossing the BBB (Cao, Pei et al. 2002, Hill, Martin et 
al. 2012, Lalatsa, Schatzlein et al. 2014, Rizzuti, Nizzardo et al. 2015). Further, our recent study 
in cardiac arrest implicated TRPM2 channel inhibition of GSK-3β in long-term functional deficits 
(Dietz, Cruz-Torres et al. 2019). Consistent with this, data presented here shows that tatM2NX 
prevents oxidative stress-induced activation (dephosphorylation) of GSK-3β. In 
electrophysiological experiments in mammalian cultures expressing the human TRPM2 
channel, tatM2NX inhibits with similar high potency as JNJ-28583113 (Fourgeaud, Dvorak et al. 
2019) and scalaradial, another potent TRPM2 antagonist that also targets TRPM7 (Starkus, 
Poerzgen et al. 2017). Further, we previously assessed specificity of tatM2NX for TRPM2 
(Shimizu, Dietz et al. 2016) by showing no additional efficacy in TRPM2-/- mice on 
neuroprotection following stroke. Additionally, TRPM2 expression in other organs magnifies the 
use of tatM2NX in a variety of non-neurological disease models (Lange, Yamamoto et al. 2009, 
Park, Chun et al. 2016, Almasi, Kennedy et al. 2018).  
TatM2NX is a cell-permeable inhibitor with high potency, which makes extensive non-
covalent interactions and favorable contacts with a number of residues of the ADPR binding site 
within the NUDT9-H domain. Many of these interactions were predicted and maintained in the 
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tat Cterm peptide. In contrast, there were no predicted interactions between tatWV-AA and the 
ADPR binding site. Furthermore, both tatM2NX and tat Cterm exhibited competitive inhibition in 
mammalian cell cultures, providing validation of the in silico predictions. Taken together, these 
data provide a mechanistic rationale for the observed inhibition of TRPM2 channels. Beyond the 
characterization of tatM2NX as a novel TRPM2 antagonist, our aim is to provide a research tool 
that will move the field of TRP channels forward and aid in specifically studying TRPM2 
molecular mechanisms in cell physiology and pathophysiology of diseases. The peptide 
tatM2NX will serve as a potential source of a new generation of derivatives that may be more 

























Figure 2.1. Molecular modeling of tatM2NX with human TRPM2 channel NUDT9-H 
domain. A) Predicted secondary structure of tat-M2NX after MD-based refinement. The 
peptide is oriented N-term (left) to C-term (right), tatHIV sequence on the N-terminus 
(dashed line). B) Top three predicted TPRM2-tatM2NX complexes, arrowhead indicates the 
human ADPR binding site within the NUDT9-H domain. C) Top scoring initial TPRM2-
tatM2NX complex (left) and the same complex after 5ns of MD simulation (right). TatM2NX 





Table 2.1 Description of peptides 
Peptide Concentration Description 
TatM2NX 0.05-10µM 
Cell permeable, parent peptide 
YGRKKRRQRRRGSREPGEMLPRKLKRVLRQEFWV 
TatWV-AA 2µM 
Parent peptide, residues mutated to Alanine 
YGRKKRRQRRRGSREPGEMLPRKLKRVLRQEFAA 
Tat Cterm 2µM 
Truncated peptide 
YGRKKRRQRRRKLKRVLRQEFWV 





















Table 2.2 TatM2NX non-covalent interactions 
Interaction (A=TPRM2, 
E=Peptide) 
Interaction Category Interaction Type 
A:ARG1280:HH21 - 








E:VAL34:OXT Hydrogen Bond; Electrostatic 
Salt Bridge; 
Attractive Charge 
A:LYS1401:NZ - E:VAL34:O Electrostatic Attractive Charge 
A:ARG1433:NH1 - 
E:GLU31:OE2 Electrostatic Attractive Charge 
A:ARG1433:NH2 - E:VAL34:O Electrostatic Attractive Charge 
E:ARG9:NH2 - A:GLU121:OE2 Electrostatic Attractive Charge 
A:TYR1349:HH - E:VAL34:OXT Hydrogen Bond Conventional Hydrogen Bond 
A:LEU1381:H - E:GLN30:OE1 Hydrogen Bond Conventional Hydrogen Bond 
A:SER1382:H - E:GLN30:OE1 Hydrogen Bond Conventional Hydrogen Bond 
A:GLY1389:H - E:PHE32:O Hydrogen Bond Conventional Hydrogen Bond 
A:SER1391:HG - E:GLU31:O Hydrogen Bond Conventional Hydrogen Bond 
A:SER1391:HG - E:VAL34:O Hydrogen Bond Conventional Hydrogen Bond 
A:LYS1401:HZ3 - E:GLU31:O Hydrogen Bond Conventional Hydrogen Bond 
A:HIS1488:HE2 - E:TRP33:O Hydrogen Bond Conventional Hydrogen Bond 
E:ARG6:HE - A:PHE108:O Hydrogen Bond Conventional Hydrogen Bond 
E:ARG6:HH21 - A:PHE108:O Hydrogen Bond Conventional Hydrogen Bond 
E:LYS23:HZ1 - A:PRO1248:O Hydrogen Bond Conventional Hydrogen Bond 
E:LYS23:HZ2 - A:ASN1249:O Hydrogen Bond Conventional Hydrogen Bond 
E:GLN30:HE21 - 
A:SER1382:OG Hydrogen Bond 
Conventional 
Hydrogen Bond 




Table 2.2 Continued. TatM2NX non-covalent interactions  
A:GLY110:HA1 - E:TYR1:OH Hydrogen Bond Carbon Hydrogen Bond 
A:PRO1380:HD1 - E:GLN30:OE1 Hydrogen Bond Carbon Hydrogen Bond 
A:SER1382:HB1 - E:GLN30:OE1 Hydrogen Bond Carbon Hydrogen Bond 
A:SER1391:HB2 - E:VAL34:O Hydrogen Bond Carbon Hydrogen Bond 
A:SER1391:HB2 - E:VAL34:OXT Hydrogen Bond Carbon Hydrogen Bond 
E:ARG3:HA - A:GLN109:OE1 Hydrogen Bond Carbon Hydrogen Bond 
E:LYS23:HE1 - A:PRO1248:O Hydrogen Bond Carbon Hydrogen Bond 
E:LYS23:HE1 - A:ASN1249:O Hydrogen Bond Carbon Hydrogen Bond 
E:ARG26:HD1 - A:LEU1381:O Hydrogen Bond Carbon Hydrogen Bond 
A:CYS1250 - E:LEU20 Hydrophobic Alkyl 
E:ARG26 - A:LEU1381 Hydrophobic Alkyl 
A:PHE108 - E:ARG6 Hydrophobic Pi-Alkyl 
A:HIS1488 - E:VAL34 Hydrophobic Pi-Alkyl 
E:PHE32 - A:ARG1404 Hydrophobic Pi-Alkyl 
E:PHE32 - A:ILE1405 Hydrophobic Pi-Alkyl 
E:TRP33 - A:PRO1380 Hydrophobic Pi-Alkyl 
E:TRP33 - A:VAL1377 Hydrophobic Pi-Alkyl 







Figure 2.2. TRPM2 protein is expressed and functional in doxycycline-inducible 
HEK293 cells. A) TRPM2 expression detected in HEK293 cells treated with doxycycline 
(1µg/mL) (Dox). No expression in un-treated HEK293 cells (No Dox). B)  N-terminal FLAG-
TRPM2 is expressed in cells 16-18h after doxycyline induction (n=3). Biotin-tatM2NX is 
present in cells within 1h incubation in the media (yellow arrows). ICC: DAPI (blue), N-
terminal-FLAG-TRPM2 (green), biotin-tatM2NX (red). C) Rundown (ADPRf) current density 
is significantly decreased from ADPRi current, while CTZ completely inhibits ADPRf. D) No 
TRPM2 activity is observed in HEK293 cells in the absence of doxycyline (No Dox). E) 
ADPRf compared to 0.05µM tatM2NX (ineffective concentration, same group as Figure 




Figure 2.3 The peptide tatM2NX inhibits TRPM2 currents in a concentration-
dependent manner. A) Representative TRPM2 initial currents (ADPRi, 3-4nA) 
activated by 100µM ADPR (red), with 2µM tatM2NX (black), or 20µM CTZ (gray).  
B) TRPM2 current density at 0.15-10µM tatM2NX compared to TRPM2 current at 
0.05µM tatM2NX (ineffective concentration control). C) Dose-response curve showing 
normalized response (current density) vs. tatM2NX concentration. Potency was 
determined normalizing each concentration to TRPM2 current density with 0.05µM 
tatM2NX. Data represented as mean±SEM and statistical significance established at 




Figure 2.4 TRPM2 forms a complex with tatM2NX in vitro, inhibits GSK3β 
signaling, and competes with ADPR to antagonize TRPM2. A) Co-
immunoprecipitation of biotin-tagged tatM2NX with FLAG-tagged TRPM2 in 
doxycycline-inducible HEK293 cells (+). No pulldown of FLAG-TRPM2 with biotin-
tatM2NX in un-induced cells (-). At least 3 independent experiments (n=3). Input: 
(+) TRPM2 expression; (-) No TRPM2 expression; Dox=doxycycline treatment 
(1µg/mL). IP: (1) streptavidin-agarose conjugated beads (beads)+cell lysate (Dox), 
(2) beads+biotin-tatM2NX (No Dox), (3) beads+biotin-tatM2NX+cell lysate (Dox), 
(4) beads+biotin-tatM2NX+cell lysate. B) Western blot of HEK293 cells expressing 
TRPM2 treated with 250µM H2O2 compared to untreated cells (Con) and cells pre-
incubated with 2µM tatM2NX for 30min-4h followed by H2O2 stimulation (10min). C) 
ADPRf (control) currents with 500µM ADPR in the presence of 0 or 2µM tatM2NX. 
No significant differences in ADPRi for control and 2µM tatM2NX. Data represented 
as mean±SEM, n≥4 (at least 3 experimental days/condition), ADPRf= final ADPR 













Figure 2.5 Molecular modeling of tat Cterm and tatWV-AA with human TRPM2 channel 
NUDT9-H domain. A) Top three scoring clusters of tatM2NX (cyan), tat Cterm (green), and 
tatWV-AA (red) in complex with a single monomer of TPRM2 (orange). B) Predicted 
secondary structure of tatM2NX (cyan) compared to tat Cterm (green) and tatWV-AA (red) 
after MD-based refinement. Peptides are oriented N-term (left) to C-term (right). C) Top 
scoring initial TPRM2-tat Cterm complex (left) and the same complex after 5ns of MD 
simulation (right). D) Top scoring initial TPRM2-tatWV-AA complex (left) and the same 
complex after 5ns of MD simulation (right).  
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Table 2.3 Tat Cterm non-covalent interactions 
Interaction (A=TPRM2, 
E=Peptide) 
Interaction Category Interaction Type 
A:ARG1336:HH12 - E:GLU20:OE2 Hydrogen Bond; Electrostatic 
Salt Bridge; Attractive 
Charge 
A:ARG1392:HH22 - E:VAL23:O Hydrogen Bond; Electrostatic 
Salt Bridge; Attractive 
Charge 
E:LYS5:HZ2 - A:GLU71:OE1 Hydrogen Bond; Electrostatic 
Salt Bridge; Attractive 
Charge 
E:ARG6:HH22 - A:ASP148:OD2 Hydrogen Bond; Electrostatic 
Salt Bridge; Attractive 
Charge 
E:ARG9:HH11 - A:ASP148:OD1 Hydrogen Bond; Electrostatic 
Salt Bridge; Attractive 
Charge 
A:ARG1336:NH2 - E:GLU20:OE1 Electrostatic Attractive Charge 
A:ARG1392:NH1 - E:VAL23:OXT Electrostatic Attractive Charge 
A:ARG1433:NH1 - E:VAL23:O Electrostatic Attractive Charge 
E:TYR1:N - A:GLU71:OE1 Electrostatic Attractive Charge 
E:ARG6:NH1 - A:ASP148:OD2 Electrostatic Attractive Charge 
E:ARG6:NH2 - A:ASP148:OD1 Electrostatic Attractive Charge 
E:ARG6:NH2 - A:ASP289:OD1 Electrostatic Attractive Charge 
E:ARG9:NH1 - A:ASP289:OD1 Electrostatic Attractive Charge 
E:TRP22:HE1 - A:TYR1485:OH Hydrogen Bond Conventional Hydrogen Bond 
E:LYS5:HE1 - A:GLU71:O Hydrogen Bond Carbon Hydrogen Bond 
E:ARG9:HD2 - A:ASP148:OD1 Hydrogen Bond Carbon Hydrogen Bond 
E:ARG6:NH2 - A:PHE75 Electrostatic Pi-Cation 
A:LEU1381:C,O;SER1382:N - 
E:TRP22 Hydrophobic Amide-Pi Stacked 
A:PRO150 - E:LYS5 Hydrophobic Alkyl 
A:HIS118 - E:ARG3 Hydrophobic Pi-Alkyl 
E:TRP22 - A:LEU1381 Hydrophobic Pi-Alkyl 






Figure 2.6 The C-terminus of tatM2NX is sufficient to antagonize TRPM2. 
A) TRPM2 current density in the presence of 2µM tat Cterm (blue), tatWV-AA (sky blue), or tat 
Nterm (green). All peptides were compared to control group (ADPRf). B) Representative 
images for Ca2+ imaging experiments at Time 0min and 20min for 250µM H2O2 (control) or 
H2O2 + 2µM tatM2NX. Fluo5F, AM (5µM, green) is the fluorescent Ca2+ indicator. C) 
Quantification of changes in fluorescence/baseline fluorescence (F/F0) for each peptide 
(2µM). TatM2NX and tat Cterm significantly inhibit TRPM2 activity in HEK293 cells. F/F0, 
corresponding to TRPM2 activity, is inhibited by 20µM CTZ (positive control). D) Area under 
the curve (AUC) analysis for each peptide: H2O2 control (black), tatM2NX (red), tat Cterm 
(blue), tatWV-AA (sky blue), tat Nterm (green). tatM2NX, tat Cterm, and CTZ significantly 
decreased AUC for TRPM2 activity, while tatWV-AA significantly increased AUC. One-way 
ANOVA with Dunnett’s post-hoc for multiple group comparison, significance established as 















Figure 2.7 No changes in ADPRi current density or frequency distribution in Ca2+ 
fluorescence in the presence of peptides. A) ADPRi current density was significant 
(p=0.03, n=6) for the peptide tat Cterm. B) Histogram of number of events vs. frames 
(20min=120 frames) in HEK293 cells expressing TRPM2 in response to H2O2 in the 
presence of peptides. All electrophysiology data represented as mean ±SEM, statistical 
significance at p<0.05 for n≥4-10 (at least 3 experimental days/condition). For Ca2+ imaging, 




INCREASED TRPM2 ACTIVITY IN GLOBAL CEREBRAL ISCHEMIA IMPAIRS 
HIPPOCAMPAL LONG-TERM POTENTIATION AND COGNITIVE FUNTION 
Introduction and review of the literature 
Global cerebral ischemia resulting from CA occurs in approximately 560,000 people in 
the United States (Benjamin, Muntner et al. 2019) leading to major cognitive disability in patients 
(Tiainen, Poutiainen et al. 2007, Cronberg, Lilja et al. 2009, Moulaert, Verbunt et al. 2009, 
Mateen, Josephs et al. 2011, Beesems, Wittebrood et al. 2014). Metabolic failure and ionic 
imbalance following global ischemia results in cell death of vulnerable neuronal populations 
including hippocampal CA1 pyramidal cells (Horn and Schlote 1992, Deng, Yonchek et al. 
2014). It is increasingly clear that in addition to neuronal injury following cerebral ischemia, 
impaired neuronal networks contribute to long-term functional deficits. In fact, despite the 
identification of numerous compounds reducing brain injury in experimental models of cerebral 
ischemia, translation to the clinic and improved outcomes in humans has been unsuccessful. 
Therefore, there is increased interest in developing therapeutic options that do not rely on 
neuroprotection to improve functional recovery (Clarkson, Huang et al. 2010, Carmichael 2012, 
Lin, Dong et al. 2017, Orfila, Grewal et al. 2017, Orfila, McKinnon et al. 2018, Joy, Ben Assayag 
et al. 2019). What remains unclear is whether interventions administered beyond ischemic cell 
death-time points can rescue neuronal networks, such as those in the hippocampus, to rescue 
synaptic plasticity and improve long-term cognitive recovery. In our laboratory, we have focused 
on synaptic plasticity in the surviving hippocampal network after cerebral ischemia, which is the 
                                                             
3 Portions of this chapter were previously published in Translational Stroke Research and are included 
with permission of the copyright holder. Citation: Dietz, R.M., Cruz-Torres, I., Orfila, J.E. et al. Transl. 
Stroke Res. (2019). https://doi.org/10.1007/s12975-019-00712-z. 
R.M.D. and J.E.O. helped with electrophysiology experiments, O.P. helped with behavioral studies, 
N.C. performed surgeries, I.C.T. performed WB, electrophysiology, and histology with helped from 
J.Y., I.C.T. wrote and analyzed the paper with input from R.M.D., N.Q., and P.S.H.  
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leading model for the cellular changes that underlie learning and memory. Thus, we have 
utilized electrophysiological recordings of hippocampal LTP as an indicator of network health 
and synaptic dysfunction following cerebral ischemia. Therefore, an optimal therapeutic 
intervention would have the capacity to reduce neuronal injury, maintain functional neuronal 
networks, and have the potential to recover cognitive function if administered in the subacute to 
late chronic ischemia phases.  
Our CA/CPR mouse model displays impairment of long-term potentiation in CA1 
hippocampal neurons and functional learning and memory for at least a month after cardiac 
arrest (Orfila, Shimizu et al. 2014); however, the underlying molecular mechanisms remain 
elusive. TRPM2 is a Ca2+ permeable channel activated by oxidative stress. In the brain, TRPM2 
expression is widespread throughout the hippocampus, cerebellum, and cortex (Fonfria, 
Murdock et al. 2006), and has been implicated in pathologies such as Alzheimer’s disease, 
dementia, bipolar disorder and cerebral ischemia (Rempe, Takano et al. 2009, Jia, Verma et al. 
2011, Alim, Teves et al. 2013, Jang, Lee et al. 2015, Ostapchenko, Chen et al. 2015, Alawieyah 
Syed Mortadza, Sim et al. 2018). TRPM2 has sexually dimorphic roles in cell death and we 
have previously shown TRPM2 inhibition is neuroprotective only in males following focal and 
global cerebral ischemia (Jia, Verma et al. 2011, Nakayama, Vest et al. 2013, Shimizu, Macey 
et al. 2013, Quillinan, Grewal et al. 2015, Shimizu, Quillinan et al. 2016, Shimizu, Dietz et al. 
2016). In contrast, TRPM2 plays a minimal role in regulating hippocampal LTP (Xie, Belrose et 
al. 2011). However, the role of TRPM2 in hippocampal synaptic function following cerebral 
ischemia remains unknown and is the focus of the current study. Despite significant progress 
using transgenic mice, the lack of a specific TRPM2 channel antagonist has slowed efforts to 
unravel intrinsic neuronal TRPM2 function in cerebral ischemia and other neurological diseases. 
Therefore, we aimed to determine the role of TRPM2 in synaptic plasticity impairment following 
global cerebral ischemia using our recently described novel inhibitor of TRPM2, tatM2NX 
(Shimizu, Dietz et al. 2016).  
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Here, we used our in vivo mouse model of CA/CPR (Nakayama, Vest et al. 2013, Deng, 
Carter et al. 2014, Deng, Yonchek et al. 2014, Orfila, Shimizu et al. 2014, Dietz, Deng et al. 
2016) to investigate the role of TRPM2 activation in cognitive dysfunction observed in male and 
female mice after global cerebral ischemia. We hypothesize that TRPM2 is persistently 
activated at hippocampal CA3-CA1 synapses, leading to long-term LTP and memory 
impairments. We also provide evidence for TRPM2-dependent CaN-GSK3β signaling that 
contributes to LTP impairments. Therefore, this paper presents data that suggest a novel 
therapeutic strategy that provides benefit to hippocampal function when administered at acute 
or delayed times after injury, thus offering higher potential for clinical translation. 
Results 
Acute TRPM2 inhibition protects male neurons after CA/CPR but protects LTP in both sexes 
 We recently developed a new peptide inhibitor of TRPM2 allowing us to perform more 
sophisticated pharmacology studies on the role of TRPM2 in acute and long-term functional 
outcomes. Global cerebral ischemia causes selective neuronal cell death in sensitive brain 
regions, such as hippocampus. We first sought to determine whether tatM2NX provides 
histological protection, therefore we tested the effect of acute administration of tatM2NX 
(20mg/kg, iv, dose chosen based upon our recent study (Shimizu, Dietz et al. 2016)) or 
scrambled peptide (tatSCR; 20mg/kg) intravenously 30min after reperfusion. Inhibition of 
TRPM2 by tatM2NX reduced neuronal injury in male mice compared to tatSCR (tatSCR: 
44.9±7.5%, n=12 vs. tatM2NX: 20.0±5.1%, n=12, p<0.05, Figure 3.1A, B, I). In females, 
inhibition of TRPM2 30min after reperfusion did not decrease hippocampal injury (tatSCR: 
36.8±7.7%, n=8 vs. tatM2NX: 45.6±6.4%, n=8, p=0.39, Figure 3.1C, D, I). This is consistent 
with our previous work demonstrating male-specific neuroprotection with TRPM2 inhibition or 
knock-down (Jia, Verma et al. 2011, Nakayama, Vest et al. 2013, Shimizu, Macey et al. 2013, 
Shimizu, Dietz et al. 2016). We used mice lacking TRPM2 expression (TRPM2-/-) to confirm our 
pharmacological data. Histological assessment 3 days after global ischemia showed that 
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TRPM2-/- male mice had reduced CA1 neuronal injury compared to wild type mice (19.2%, n=7 
vs. 46.0% , n=8, respectively, p<0.05, Figure 3.1E, F, J). In contrast, CA/CPR in TRPM2-/- 
female mice had no impact on cell death, showing equivalent CA1 neuronal injury compared to 
WT (16.9%, n=9 vs. 19.4%, n=9, respectively, Figure 3.1G, H, J). Female mice had less injury 
than male mice, independent of genotype, consistent with previous reports of reduced ischemic 
sensitivity in females (Herson and Hurn 2010).  
We next tested whether administration of tatM2NX 30min after CA/CPR provides long-
term benefit on hippocampal function in a sexually dimorphic manner as observed for 
neuroprotection (Figure 3.2A). We previously reported that CA/CPR in male mice impairs 
synaptically evoked NMDAR-dependent LTP when examining extracellular field recordings in 
acute hippocampal slices prepared 7 days after ischemia (Orfila, Shimizu et al. 2014, Deng, 
Orfila et al. 2017). This represents the sub-acute phase of recovery when cell death processes 
are complete and we can assess the function of surviving CA1 neurons. Here we confirm LTP 
impairment after CA/CPR in male mice by comparing the percent increase in synaptic response 
(in relation to baseline, set at 100%) in ischemic animals with sham controls at 7 days. In slices 
from sham mice, a brief theta burst stimulus (TBS: 40 pulses, 100Hz) at CA3 (Schaffer 
collateral)-CA1 synapses resulted in LTP that increased the slope of the field excitatory 
postsynaptic potential (fEPSP) to 161±9.2% of baseline (n=6, Figure 3.2B, C, D) after 60min. In 
contrast, recordings obtained in slices from CA/CPR mice exhibited impairment of LTP with a 
fEPSP slope of 109±3.5% of baseline (n=6; p<0.05, compared to sham, p<0.05 compared to 
sham, Figure 3.2B, C, D). Administration of tatM2NX 30min after reperfusion prevented the 
impairment of LTP 7 days after CA/CPR (179±20.2%, n=5), recovering to sham control levels 
(p<0.05 compared to CA/CPR, Figure 3.2B, C, D). There was no effect of tatM2NX on LTP in 
sham mice 7 days after surgery (160±7.0, n=8, p>0.05 compared to sham). Similar to males, we 
observed an LTP deficit in female mice 7 days after recovery from CA/CPR compared to shams 
(Sham: 160±7.4%, n=6; CA/CPR: 105±4.8%, n=6, p<0.05, Figure 3.2E, F, G). Despite the lack 
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of histological protection with tatM2NX in females, we observed protection of LTP 7 days after 
CA/CPR, with an increase to 153.4±5.7% of baseline when tatM2NX was administered 30 min 
after reperfusion (n=6, p<0.05 compared to CA/CPR, Figure 3.2E, F, G). There was no effect 
on input-output curves or paired-pulse ratios by global cerebral ischemia or tatM2NX in male or 
female mice (Table 3.1). Consistent with acute pharmacologic inhibition, knockout of trpm2 
gene preserved LTP 7 days after CA/CPR in both sexes (male TRPM2-/- after CA/CPR: 
166.6±7.7%, n=7, p>0.05 compared to WT, Figure 3.2C, D); female TRPM2-/- after CA/CPR: 
155.9±10.1%, n=7, p>0.05 compared to WT, Figure 3.2F, G). These data suggest that 
ischemia-induced activation of synaptic TRPM2 channels contributes to synaptic plasticity 
deficits in both sexes. This remarkable observation of synaptic protection in females without 
neuroprotection suggests disparate pathways involved in cell death and synaptic dysfunction. 
Delayed TRPM2 inhibition reverses CA/CPR-induced synaptic impairments 
 In light of our novel observation that TRPM2-mediated signaling contributes differently to 
cell death and synaptic dysfunction, we next aimed to determine whether TRPM2 inhibition is 
beneficial at delayed time points when cell death processes are complete (>3 days (Deng, 
Yonchek et al. 2013)) and synaptic dysfunction is present in the surviving network.  Male and 
female mice were injected with tatM2NX (20mg/kg iv (Shimizu, Dietz et al. 2016)) on day 6 after 
CA/CPR and hippocampal slices were prepared for LTP experiments the next day, on day 7 
after CA/CPR (Figure 3.3A). In vivo inhibition of TRPM2 channels resulted in recovery of 
synaptic plasticity to sham levels in male (167.6±8.8%, n=8, p<0.05 compared to sham, Figure 
3.3B, C) and female (175.5±13.6%, n=6, p<0.05 compared to sham, Figure 3.3D, E) CA/CPR 
mice. We extended our in vivo observation to ex vivo brain slice experiments in order to 
elucidate rapid signaling mechanisms. Brain slices prepared for field recording 7 days after 
CA/CPR were incubated in tatM2NX or tatSCR (1µM in aCSF) for 2h prior to LTP experiments 
(ex vivo). Inhibition of TRPM2 at this delayed time point resulted in reversal of LTP impairment 
(154.0±6.7%, n=9, p<0.05 compared to 7d CA/CPR (Figure 3.3F, G). Ischemia and delayed 
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administration of tatM2NX had no effect on presynaptic release (paired pulse stimulation) or 
axonal excitability as shown by input-output (I/O) response (Table 3.2). These data indicate that 
ischemia causes persistent synaptic TRPM2 channel activity which actively impairs plasticity. To 
assess whether this ischemia-induced increase in TRPM2 activity is related to TRPM2 
expression, we performed quantitative RT-PCR. We did not observe increased TRPM2 channel 
mRNA expression consistent with increased activity (Figure 3.3H). We were unable to directly 
measure TRPM2 protein levels as Western blots using commercially available anti-TRPM2 
antibodies are non-specific, as they showed positive bands in TRPM2-/- mice (Figure 3.4).  
Ischemia and delayed administration of tatM2NX had no effect on presynaptic release 
(paired pulse stimulation) or axonal excitability as shown by input-output response (Table 3.2). 
These data indicate that ischemia causes persistent synaptic TRPM2 channel activity, which 
actively impairs plasticity. To assess whether this ischemia-induced increase in TRPM2 activity 
is related to TRPM2 expression, we performed quantitative RT-PCR. We did not observe 
increased TRPM2 channel mRNA expression consistent with increased activity (Figure 3.3H). 
As above, we were unable to directly measure TRPM2 protein levels as Western blots using 
commercially available anti-TRPM2 antibodies showed positive bands in TRPM2-/- mice (Figure 
3.4).  
Delayed inhibition of CaN and GSK3β rescues synaptic function 
We next tested possible downstream targets that contribute to TRPM2-induced LTP 
impairments following global cerebral ischemia. In light of recent studies showing TRPM2 
alterations of long-term depression via increased GSK3β signaling (Xie, Belrose et al. 2011), we 
hypothesize that TRPM2-induced Ca2+ influx activates CaN and consequently increased 
GSK3β. To assess the role of CaN on post-ischemic LTP deficits, we used cyclosporine A (CsA) 
or FK-506 (FK) to inhibit CaN in acute slices taken from mice 7 days after recovery from 
CA/CPR in male mice. Figure 3.5 shows that bath application of CsA (1µM) for 1h reverses the 
CA/CPR-induced loss of LTP in acute slices, recovering to 158±9.4% (n=9, p<0.05 compared to 
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sham CsA treated slices, Figure 3.5B, C).There was no effect of CsA on sham slices (Figure 
3.5B, C). Importantly, CsA had no effect on presynaptic release (paired pulse stimulation) or 
axonal excitability as shown by input-output response (Table 3.3). We used a second CaN 
inhibitor to confirm our data showing a role for CaN activity in ischemia-induced LTP deficits. 
Consistent with our CsA data, FK-506 also reversed CA/CPR induced synaptic impairment after 
1h incubation (10μM), recovering to 156±11.2% (n=5, p<0.05 compared to CA/CPR, Figure 
3.5B, C). FK-506 did not affect LTP in sham slices, nor did it change paired pulse stimulation or 
I/O response (Table 3.2). 
To assess the role of GSK3β, we used two GSK3β inhibitors (CT99027 (CT), tideglusib 
(TDG)) in our ex vivo LTP experiments. Figure 3.5 shows that exposure of post-ischemic slices 
to the GSK3β inhibitor CT (1μM) for 1h reversed LTP impairment, recovering to 169±5.6% (n=7, 
p<0.05 compared to CA/CPR, Figure 3.5D, E). Consistent with previous reports (Jo, Whitcomb 
et al. 2011), bath application of CT had no effect on the induction of LTP in sham control slices 
(Figure 3.5E). A different and more specific GSK3β inhibitor TDG (Hicks, VanBrocklin et al. 
2010), was also tested. Post-ischemic hippocampal slices exposed to TDG (1μM) displayed 
reversed LTP impairment, recovering to 170±10.1%, (n=5, p<0.05 compared to CA/CPR, 
Figure 3.5D, E). TDG had no effect on sham slices (Figure 3.5E). Finally, to causally link 
TRPM2 activity and GSK3β activity, post-ischemic hippocampal slices were exposed to 
tatM2NX (1μM) for 2h in combination with TDG (1μM). We observed similar recovery of LTP 
(173±8.7%, n=5, p>0.05, Figure 3.5E) compared to either drug alone. There was no effect of 
this combination of drugs on sham LTP (Figure 3.5E), paired pulse stimulation or I/O responses 
(Table 3.3). Together, these data indicate that TRPM2 channels impair synaptic activity via 
CaN-GSK3β signaling following global cerebral ischemia. To determine the effect of persistent 
TRPM2 channel on hippocampal function, we performed contextual fear conditioning to analyze 
hippocampal-dependent learning and memory (Uchida, Palmateer et al. 2009, Zhu, Wang et al. 
2010).  Figure 3.6 shows that sham mice administered control peptide (tatSCR, 20mg/kg, ip) 
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exhibited intact memory, as evidence by freezing behavior in 55.1±4.4% of time epochs (n=11) 
24h after training. However, mice 7 days after CA/CPR administered tatSCR demonstrated 
decreased freezing (35.5±4.9%, n=12, p<0.05), indicating impairment in memory. Male mice 
tested 7 days after recovery from CA/CPR given tatM2NX (20mg/kg, ip) on day 6 after CA/CPR 
exhibited recovery of memory function (59.1±6.0%, n=12), similar to sham control levels. In the 
absence of ischemia, tatM2NX did not improve memory function (56.3±4.6%, n=11), indicating 
an ischemia-specific role for TRPM2 channels in memory function (Figure 3.6B). Female mice 
exhibited similar recovery of learning and memory after delayed inhibition of TRPM2 channels 
(Figure 3.6C). One week after sham surgery, female mice given tatSCR exhibited freezing 
behavior in 58.6.1±4.2% (n=8) of time epochs 24h after training. Females given tatSCR after 
CA/CPR had decreased freezing (42.5±3.5%, n=8, p<0.05). Administration of tatM2NX reversed 
memory impairments after CA/CPR (63.4±3.4%, n=8) and had no effect after sham surgeries 
(60.3±4.7%, n=8). The benefit of delayed tatM2NX administration on memory behavior are 
consistent with our electrophysiology data showing that delayed administration of tatM2NX 
reverses ischemia-induced LTP deficits.   
We went on to test whether administering tatM2NX at a chronic time point (four weeks) 
after CA/CPR had a similar effect (Figure 3.6D, E). Male mice were given a single injection of 
tatM2NX or tatSCR (20mg/kg, ip) on day 29 after CA/CPR or sham surgeries. There was no 
difference between tatM2NX and tatSCR in sham mice (72±5.4% and 67±5.9%, respectively, 
n=6 each, Figure 3.6). CA/CPR mice receiving tatSCR froze 44±4.5% (n=11), consistent with a 
persistent memory impairment at 30 days after CA/CPR. However, inhibition of TRPM2 with  
tatM2NX in mice having undergone CA/CPR rescued memory formation to sham levels with 
mice freezing 66±4.2% of the time (n=12, p<0.05).  
Discussion   
The results presented here are consistent with several recent studies showing that 
ischemia causes a persistent impairment of hippocampal LTP (Orfila, Shimizu et al. 2014, Orfila, 
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Grewal et al. 2017, Dietz, Orfila et al. 2018) and importantly that these LTP deficits correlate 
well with our behavioral data indicating impairments in memory and learning function. Our new 
data show that inhibition of TRPM2 channels (with tatM2NX) 7 days after recovery from cerebral 
ischemia (in vivo or ex vivo) reverses ischemia-induced deficits in synaptic plasticity and 
improves memory function in both males and females. This delayed administration of a 
pharmacological agent to enhance synaptic function in the hippocampus is a unique approach 
to improve recovery. While a unique approach to reduce ischemia-induced memory 
complications, our data is consistent with several recent studies showing that delayed treatment 
can improve sensorimotor function following experimental stroke (Clarkson, Huang et al. 2010, 
Carmichael 2012, Lin, Dong et al. 2017, Joy, Ben Assayag et al. 2019). Further, we show that 
treatment with tatM2NX one month after recovery from cardiac arrest reverses the stable 
memory deficit observed. A major roadblock in the study of TRPM2 channels in brain ischemia 
and neurodegenerative disease has been the lack of specific inhibitors that are amenable to use 
in vivo. Our recent study was the first to report the safety and efficacy of our novel TRPM2 
channel inhibitor to reduce brain injury following experimental stroke (Shimizu, Quillinan et al. 
2016, Shimizu, Dietz et al. 2016). The lack of additional effect of tatM2NX in TRPM2-/- mice 
provides strong evidence for specificity. Consequently, tatM2NX serves as an important new 
pharmacological tool in the current study to understand how TRPM2 is involved in hippocampal 
function in ischemic mice. Therefore, our novel strategy of delayed TRPM2 inhibition with a 
novel specific inhibitor unlocks important new therapeutic avenues following cerebral ischemia, 
and potentially other neurologic diseases associated with memory deficits due to TRPM2.  
A role for TRPM2 channels in mediating ischemia/reperfusion injury in the brain has 
been proposed for several years (Rempe, Takano et al. 2009, Szydlowska and Tymianski 2010, 
Miller and Zhang 2011). However, we were the first to directly demonstrate the role of TRPM2 
channels following experimental stroke, making the remarkable observation that inhibitors, and 
knockdown, of TRPM2 reduce ischemic injury following experimental stroke (MCAO) in the male 
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brain, while having no effect in the female brain (Jia, Verma et al. 2011, Shimizu, Macey et al. 
2013). Other studies using male TRPM2-/- mice demonstrate similar neuroprotection (Alim, 
Teves et al. 2013, Gelderblom, Melzer et al. 2014, Toda, Yamamoto et al. 2019), although none 
of these studies used female mice to confirm our observation regarding male-specific role of 
TRPM2 channels in neuroprotection. We have gone on to confirm this initial observation and 
demonstrate the same sex-specific phenomena following global cerebral ischemia (Nakayama, 
Vest et al. 2013) and in vitro (Verma, Quillinan et al. 2012). Our recent data has shed some light 
on the mechanism of sex-specific activation of TRPM2 during the acute phase, implicating 
male-specific activation of PARP-1 as the upstream mediator of TRPM2 channel engagement in 
the male brain following ischemia (Shimizu, Macey et al. 2013). In contrast, data presented in 
the current study demonstrates that despite male-specific neuroprotection in TRPM2-/- mice and 
acute tatM2NX treated mice, both male and female mice show improved synaptic plasticity and 
memory function when TRPM2 is inhibited or genetically knocked out. These data indicate 
disparate signaling pathways engaging TRPM2 in cell death in males only and TRPM2-
mediated synaptic dysfunction of surviving neurons observed in both male and females.  
This study presents evidence for the first time that ischemia causes sustained TRPM2 
activity that impairs synaptic plasticity and memory function after cardiac arrest-induced global 
cerebral ischemia. The rapid reversal of LTP deficits in acute brain slices provides strong 
evidence that ischemia causes aberrant synaptic TRPM2 channel activity. It was recently shown 
that TRPM2-/- mice have reduced hippocampal NMDAR function (Alim, Teves et al. 2013). 
However, our data shows that acute inhibition of TRPM2 channels does not impair NMDAR 
function, as tatM2NX administered either in vivo or ex vivo increases NMDAR-dependent LTP in 
post-ischemic mice. Further, our recent studies indicate intact NMDAR activity 7 and 30 days 
after global cerebral ischemia (Orfila, Shimizu et al. 2014, Dietz, Deng et al. 2016). Importantly, 
our data in sham control animals show no effect of tatM2NX on excitability or LTP, consistent 
with recent studies showing no effect of TRPM2 channels on hippocampal LTP (Xie, Belrose et 
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al. 2011). This is an important finding as it increases the clinical impact of using TRPM2 channel 
inhibitors that restore LTP without affecting physiological signaling. 
The mechanism of ischemia-induced increase in TRPM2 channel activity in the 
hippocampus remains to be determined. Our current data shows no increase of TRPM2 channel 
expression 7-30 days following ischemia, implicating upstream signaling pathways in TRPM2 
channel activity following ischemia. To attempt to understand the mechanism of ischemia-
induced activation of TRPM2 channels during these delayed time-points, we interrogated 
several proteins known to regulate TRPM2 channel activity. TRPM2 channels are activated by 
increased levels of intracellular ADPR. In particular, it has been demonstrated that ADPR 
generated following activation of PARP-1 stimulates TRPM2 channel activity (Fonfria, Marshall 
et al. 2004, Miller 2004, Yang, Chang et al. 2006) and we have observed this pathway as 
fundamental in the sex-specific activation of TRPM2 channels during the acute phase following 
cerebral ischemia (Fairbanks, Vest et al. 2013, Shimizu, Macey et al. 2013). Quantification of 
PARP-1 mRNA at delayed time-points (7 and 30 days), showed a small decline in expression 
(Figure 3.7). Therefore, PARP-1 is unlikely to explain the enhanced activity observed at these 
delayed time-points. In addition, PARP-1 is a nuclear protein and thus generates increased 
ADPR within the soma of neurons, which is not consistent with the increased channel activity 
implicated in the current study. Similarly, the enzyme SIRT2, has been demonstrated to produce 
O-acetyl-ADPR which can activate TRPM2 channels (Grubisha, Rafty et al. 2006). Figure 3.7 
illustrates that ischemia does not alter SIRT2 expression. Therefore, we hypothesize alternative 
mechanisms of TRPM2 regulation following cerebral ischemia. Unfortunately, the lack of 
specific anti-TRPM2 antibodies (Figure 3.4) limits our ability to assess post-translational 
modifications that likely impact TRPM2 channel activity. Clearly, further studies are needed to 
fully elucidate the mechanism of ischemia-induced TRPM2 channel activity. Nonetheless, the 
data presented in this study indicate that our novel TRPM2 inhibitor, tatM2NX, represents a new 
restorative therapeutic strategy, eg. pharmacological rehabilitation. 
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Lastly, our data implicates increased CaN-GSK3β signaling as the downstream mediator 
of TRPM2-induced synaptic plasticity dysfunction following ischemia. GSK3β is a serine/ 
threonine kinase enriched in neurons within the central nervous system and is involved in 
several cellular process. GSK3β contributes to ischemic brain injury, as evident by increased 
GSK3β activity following ischemia and the ability of GSK3β inhibitors to reduce ischemic brain 
injury (Kelly, Zhao et al. 2004, Endo, Nito et al. 2006). In addition to its well-established role in 
determining sensitivity to injury, GSK3β activation plays an integral role in synaptic plasticity, 
particularly the induction of long-term depression (LTD) (for review see (Peineau, Taghibiglou et 
al. 2007, Peineau, Nicolas et al. 2009, Collingridge, Peineau et al. 2010, Bradley, Peineau et al. 
2012)). Activation of LTD impairs the consequent induction of LTP. Therefore, we hypothesize 
that ischemia activates intracellular signaling pathways involved in LTD, thereby 
inhibiting/impairing LTP. A recent study showed that that TRPM2-/- mice have impaired LTD, 
likely due to loss of GSK3β activity (Xie, Belrose et al. 2011). Relevant to our hypothesis, 
excessive activity of GSK3β impairs LTP (Hooper, Markevich et al. 2007). Our data is consistent 
with this mechanism of impaired LTP, as inhibition of GSK3β reverses ischemia-induced LTP 
deficits. We do not observe an additive impact on LTP with the co-application of the TRPM2 
channel inhibitor tatM2NX and GSK3β inhibitor, providing further evidence for TRPM2-mediated 
activation of GSK3β. The protein phosphatase CaN is a well-established regulator of GSK3β 
activity, via de-phosphorylation of the S9 residue of GSK3β. CaN is a Ca2+-activated 
phosphatase and therefore a logical mediator of TRPM2 channel activation of GSK3β. 
Consistent with this, it has recently been demonstrated that TRPM2 can activate GSK3β in 
hippocampal neurons (Xie, Belrose et al. 2011, Fourgeaud, Dvorak et al. 2019). We show here 
that ischemia-induced hippocampal dysfunction is reversed by inhibition of CaN and GSK3β. 
Thus, our data leads us to favor a model of ischemia-induced TRPM2 channel activity resulting 
in increased Ca2+, which activates the Ca2+-dependent phosphatase CaN causing GSK3β 
activation and impaired LTP. Interestingly, hippocampal dysfunction observed in models of 
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Alzheimer’s disease have also been linked to increased GSK3β activity (for review see (King, 
Pardo et al. 2014)), and a recent study showed that aged APP/PS1 Alzheimer’s mice crossed 
with the TRPM2-/- mice exhibit improved hippocampal plasticity, memory and normalized GSK3β 
activity (Ostapchenko, Chen et al. 2015). Therefore, further studies are needed to elucidate the 
shared mechanisms between acute cerebral ischemia and neurodegenerative diseases 
concerning TRPM2 channel signaling, synaptic plasticity and cognitive decline. 
Conclusions 
We provide the first direct evidence that hippocampal synaptic dysfunction can be 
targeted at delayed time points to produce reversal of chronic memory deficits following cerebral 
ischemia. We show efficacy of our novel TRPM2 channel inhibitor, tatM2NX, administered in 
vivo at time points beyond those observed for neuroprotective strategies, thus describing the 
potential neuro-restorative function of tatM2NX. We further describe that ischemia-induced 
memory deficits are mediated at least in part by aberrant activity of the TRPM2-CaN-GSK3β 
signaling cascade that actively inhibits synaptic plasticity. Our strategy of targeting delayed 
TRPM2 channel inhibition weeks to months after cardiac arrest affords a unique new 
opportunity to reverse learning and memory impairments, which could be critical to facilitate 







Figure 3.1 Acute tatM2NX reduces neuronal injury in males. Representative 
photomicrographs of hippocampal CA1 neurons from male mice injected with 
20mg/kg scrambled control peptide; tatSCR male (A) and female (C) or 20mg/kg 
tatM2NX male (B) and female (D) 30min after resuscitation. (I) Quantification of 
ischemic CA1 neurons 3 days after recovery from CA/CPR in mice treated with 
tatSCR vs tatM2NX. Representative photomicrographs of hippocampal CA1 
neurons from WT male (E) and female (G) or TRPM2-/- male (F) and female (H) 
mice 3 days after recovery from CA/CPR. J) Quantification of ischemic CA1 












Figure 3.2 Acute inhibition of TRPM2 with tatM2NX prevents synaptic plasticity 
deficits. A) Experimental timeline B) Representative trace of recordings obtained in 
MALE (i) sham, (ii) 7 days after CA/CPR and (iii) 7 days after CA/CPR mice treated at 
30min with 20mg/kg tatM2NX (iii). C) Time course of fEPSP slope from MALE mice 7 
days after CA/CPR (red), 7 days after CA/CPR mice treated at 30min with 20mg/kg 
tatM2NX (blue) and male TRPM2-/- mice 7 days after CA/CPR (open blue). D) 
Quantification of change in fEPSP slope 60min after TBS stimulation normalized to 20min 
of baseline recording. E) Representative trace of recordings obtained in FEMALE (i) 
sham, (ii) 7 days after CA/CPR and (iii) 7 days after CA/CPR mice treated at 30min with 
20mg/kg tatM2NX. F) Time course of fEPSP slope from FEMALE  mice 7 days after 
CA/CPR (red), 7 days after CA/CPR mice treated at 30min with 20mg/kg tatM2NX (blue) 
and male TRPM2-/- mice 7 days after CA/CPR (open blue). G) Quantification of change 


























































Sham  tatM2NX 30min IV 
CA/CPR tatM2NX 30min IV 
CACPR    TRPM2 KO 
p value 
PPR (pulse 2/pulse 1) 
1.45 ± 0.07 
1.58 ± 0.05  
1.41 ± 0.07  
1.51 ± 0.12  
1.47 ± 0.06  
0.46 
I/O (slope) 
2.14 ± 0.13 
2.07 ± 0.15 
2.12 ± 0.14  
1.87 ± 0.18  





























Table 3.1  Continued. I/O and PPR for acute 
neuroprotection after CA/CPR 



































































































































































Paired-pulse ratios and input-output (I/O) slope obtained in sham, CA/CPR, 
CA/CPR+tatM2NX when tatM2NX was administered at 30min and recording obtained 
on day 7 after recovery from CA/CPR. Male (top) and Female (bottom) mice. 




Figure 3.3. Delayed inhibition of TRPM2 with tatM2NX REVERSES synaptic 





















A) Experimental timeline. B) Time course of fEPSP slope from MALE mice 7 days after 
CA/CPR (red) and in mice administered 20mg/kg tatM2NX 6 days after CA/CPR and 
recordings obtained 7 days after CA/CPR (black). C) Quantification of change in fEPSP 
slope 60min after TBS stimulation normalized to 20min of baseline recording. D) Time 
course of fEPSP slope from slices obtained 7 days after CA/CPR in FEMALE mice 
(black) and in mice administered 20mg/kg tatM2NX 6 days after CA/CPR and 
recordings obtained from slices 7 days after CA/CPR (red). E) Quantification of change 
in fEPSP slope 60min after TBS stimulation normalized to 20min of baseline recording. 
F) Time course of fEPSP slope from male mice after sham surgery (black), 7 days after 
CA/CPR (red) and 7 days after CA/CPR slices treated 1µM tatM2NX for 2h prior to 
recording (open black). G) Quantification of change in fEPSP slope 60min after TBS 
stimulation normalized to 20min of baseline recording. H) Quantitative real time RT-
PCR analysis of TRPM2 mRNA expression from hippocampus obtained from sham 
mice and mice 7 or 30 days after CA/CPR. 
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PPR (pulse 2/pulse 1) 
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1.98 ± 0.12  2.07 ± 0.13  0.61 
Paired-pulse ratios and input-output (I/O) slope obtained in sham, CA/CPR, 
CA/CPR+tatM2NX when tatM2NX was administered on day 6 and recording obtained 
on day 7 after recovery from CA/CPR. Male (top) and Female (bottom) mice. 




Figure 3.4 Lack of TRPM2 antibody validation. TRPM2 expression 
(171kDa) detected in brain tissue (hippocampus and cerebellum) from Wild-
type (WT) and TRPM2-/- mice. Black arrow depicts TRPM2 band, 







Figure 3.5 Inhibition of CaN or GSK3β reverses TRPM2-mediated LTP deficits.  
A) Experimental timeline. B) Time course of fEPSP slope from MALE sham control mice 
(black), 7 days after CA/CPR (open black circles), 7 days after CA/CPR slices treated 1µM 
cyclosporine (blue) or 10µM FK-506 (red) for 1h prior to recording (blue) and sham control 
mice 7 days after 20mg/kg tatM2NX (green). C) Quantification of change in fEPSP slope 
60min after TBS stimulation normalized to 20min of baseline recording. D) Time course of 
fEPSP slope from male sham control mice (black), 7 days after CA/CPR (open black circles), 
7 days after CA/CPR slices treated 1µM CT99021 (blue) or 1µM Tidegulib (red) for 1h prior 
to recording (blue) and sham control mice 7 days after 20mg/kg tatM2NX (green). E) 
Quantification of change in fEPSP slope 60min after TBS stimulation normalized to 20min of 

















































Sham  CsA 7d 
CA/CPR CsA 7d 
Sham FK-506 7d 
CA/CPR FK-506 7d 
Sham CT99021 7d 
CA/CPR CT99021 7d 
Sham TDG 7d 
CA/CPR TDG 7d 
Sham TDG+ tatM2NX 7d 
CA/CPR TDG+ tatM2NX 7d  
p value 
         PPR (pulse 2/pulse 1) 
1.63 ± 0.03  
1.30 ± 0.06  
1.52 ± 0.15  
1.42 ± 0.06  
1.57 ± 0.14  
1.35 ± 0.06  
1.32 ± 0.06  
1.33 ± 0.07  
1.44 ± 0.10  
1.40 ± 0.06  
1.43 ± 0.05  
1.44 ± 0.05  
0.27 
I/O (slope) 
2.09 ± 0.12  
2.07 ± 0.09  
2.07 ± 0.11  
2.05± 0.11  
2.06 ± 0.11  
2.11 ± 0.13  
2.06 ± 0.07  
2.03 ± 0.16  
2.07 ± 0.13  
2.04± 0.15  
2.07± 0.14  
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Figure 3.6 Delayed inhibition of TRPM2 with tat-M2NX improves memory function.  
A) Experimental timeline. B) Quantification of freezing behavior 24 hr after fear conditioning in a 
novel environment in MALE mice administered 20mg/kg tat-M2NX 6 days after recovery from 
CA/CPR and behavior testing initiated on day 7 after CA/CPR. C) Quantification of freezing 
behavior 24h after fear conditioning in a novel environment in FEMALE mice administered 
20mg/kg tat-M2NX 6 days after recovery from CA/CPR and behavior testing initiated on day 7 
after CA/CPR. D) Experimental timeline. E) Quantification of freezing behavior 24h after fear 
conditioning in a novel environment in male mice administered 20 mg/kg tat-M2NX 29 days after 








Figure 3.7 PARP and SIRT mRNA expression in CA/CPR mice. A) Quantitative real 
time RT-PCR analysis of PARP1 mRNA expression from hippocampus obtained from 
sham mice and mice 7 or 30 days after CA/CPR. B) Quantitative real time RT-PCR 
analysis of SIRT2 mRNA expression from hippocampus obtained from sham mice and 




MATERIALS AND METHODS 
Methods for tatM2NX pharmacology 
Protein structure prediction and molecular modeling (MD) 
All MD studies were conducted using Biovia Discovery Studio 2018 (Biovia, Inc, Sand 
Diego, CA; www.3dsbiovia.com) and YASARA Structure 18.4 (YASARA Biosciences GmbH, 
Vienna, Austria; www.yasara.org). Structural coordinates for the human TRPM2 ion channel 
(Wang, Fu et al. 2018) were downloaded from the Protein Data Bank (www.rcsb.org, PDB 
accession: 6MIX). Ab initio prediction of the secondary and tertiary structures for the wild-type, 
truncated, and mutant peptides was performed using the online QUARK server 
(https://zhanglab.ccmb.med.umich.edu/QUARK/) (Xu and Zhang 2012, Xu and Zhang 2013). 
The top 5 predicted peptide structures for each designed peptide were subjected to 1 
nanosecond (ns) of explicit solvent-based molecular dynamic (MD) simulation utilizing the 
YASARA2 force field (Krieger, Nielsen et al. 2006, Krieger, Joo et al. 2009, Krieger, Dunbrack et 
al. 2012, Krieger and Vriend 2015), which combines the AMBER (ff14SB) force field (Maier, 
Martinez et al. 2015) with self-parameterizing knowledge-based potentials (Krieger, Koraimann 
et al. 2002), to refine each of the predicted peptide structures. The snapshots from the resulting 
trajectories were assessed using the WHAT_IF and WHAT_CHECK (Vriend 1990, Hooft, Vriend 
et al. 1996) structure validation tools to quantitatively evaluate the overall quality of each 
predicted structure, with the highest scoring structure for each peptide selected for further 
analysis. The ZDOCK (Chen, Li et al. 2003), ZRANK (Pierce and Weng 2007), and RDOCK (Li, 
Chen et al. 2003) algorithms were employed within Discovery Studio to predict the most likely 
protein-peptide complexes and refine their respective intermolecular interactions, as we have 
described previously (Ryan, Backos et al. 2012, Smith, Bornikova et al. 2018). To test the 
stability of the predicted interactions, we first removed the transmembrane domain of the 
TRPM2 subunit (residues 697-1165) and the top scoring complex for each peptide was placed 
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in a simulation cell under periodic boundary conditions, filled with water, 0.9% NaCl and counter 
ions, pH7.4, at a temperature of 298K (Krieger, Darden et al. 2004). The main MD simulation 
was run for 5 ns using the AMBER (ff14SB) force field (Maier, Martinez et al. 2015) with GAFF 
(Wang, Wolf et al. 2004) / AM1BCC (Jakalian, Jack et al. 2002) parameters, particle mesh 
Ewald (PME) summation, an 8.0 Å cutoff for non-bonded forces, a 5 fs time-step, LINCS-
constrained hydrogen atoms (Hess, Bekker et al. 1997), and at constant pressure and 
temperature (the NPT ensemble), as described previously (Krieger and Vriend 2015). Figures 
were generated using Lightwave 2019 (NewTek Inc, Burbank, CA; www.lightwave3d.com) and 
Marmoset Toolbag 3.07 (Marmoset, LLC, Portland, OR; www.marmoset.co).   
Cell culture 
Doxycycline-inducible N-terminal FLAG-TRPM2 expressing HEK293 cells, provided by 
Anne L. Perraud (University of Colorado Anschutz Medical Campus, CO, USA), were cultured 
as previously described (Perraud, Fleig et al. 2001, Shimizu, Dietz et al. 2016). Briefly, cells 
were grown in Advanced DMEM medium containing 10% fetal bovine serum, 2mM Glutamatax 
(Life technologies, Carlsbad, CA, USA), and MycoZap-Plus (Lonza, Switzerland). Cell line 
authentication was confirmed as female human embryonic kidney cells and mycoplasma 
contamination was negative (BioResources Core, University of Colorado, Anschutz Medical 
Campus, Aurora, CO, USA). During growth, selection markers Zeocin (1µg/ml) (Invitrogen, 
Carlsbad, CA, USA) and Blastocidin-S (0.4µg/ml) (Gibco, Carlsbad, CA, USA) were utilized for 
the selective expression of tet repressor and human TRPM2 in HEK293 cells until 80-90% 
confluence. Cells were grown for up to 20 passages (P3-P20). For Western blot experiments, 
HEK293-derived cells were maintained in Zeocin and Blastocidin-S (un-induced cells) or in 
doxycycline (1µg/mL) (induced cells) for 16-18h prior to protein lysate collection. For 
electrophysiology experiments, HEK293 cells were seeded on 12mm glass coverslips at a 
density of 12,000 cells/ml for 16-24h for doxycycline-inducible human TRPM2 expression prior 
to experiments. For Ca2+ imaging experiments, HEK293 cells were seeded on Mattek glass 
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bottom dishes (Mattek Corporation, Ashland, MA, USA) at a density of 25,000 cells/ml for 16-
24h prior to experiments.  
Western blot 
HEK293 cells were collected 16-18h after induction via centrifugation at 3,000rpm for 
3min, washed in phosphate buffered saline (1xPBS, pH 7.4), and lysed for 10min using 
neuronal protein extraction reagent (Thermo Scientific, Rockford, IL, USA). For GSK-3β 
expression and phosphorylation, HEK293 cells were pre-incubated with tatM2NX for 30min-4h 
followed by 250µM H2O2 stimulation (10min) and protein lysates collected immediately. Lysates 
were centrifuged at 12,000rpm for 15min and supernatant collected for protein quantification. 
Protein samples (15-20µg) were resolved using SDS-PAGE, and transferred in PVDF 
membranes (β-actin, 50min; TRPM2-FLAG, 90min; GSK3β, 50min). PVDF membranes were 
blocked in 5% bovine serum albumin for 1h and incubated overnight at 4°C in primary antibody. 
Human TRPM2 expression was assessed with mouse anti-FLAG (1:1000, F1804, Sigma, St. 
Louis MO, USA) (Brizzard, Chubet et al. 1994), and normalized to mouse anti-β-actin 
peroxidase (1:10000, A3854, Sigma, St. Louis, MO, USA). GSK3β phosphorylation and 
expression was assessed with rabbit anti-pGSK3 or GSK3β (1:1000, 9323S; and 1:1000, 
12456S, Cell Signaling Technology, Danvers, MA, USA). All membranes were washed 3 times, 
incubated in secondary horseradish peroxidase-conjugated goat-anti mouse (1:10000, 115-035-
003, ImmunoResearch Laboratories, USA). All membranes were washed 3 times, incubated in 
secondary horseradish peroxidase-conjugated goat-anti mouse or goat-anti rabbit antibody 
(1:10000, 115-035-174, ImmunoResearch Laboratories, USA; or 1:10000, 31460, ThermoFisher 
Scientific, USA) for 1h at room temperature. Western blot bands were detected using the 
SuperSignal™ West Femto Maximum Sensitivity Substrate (34096, ThermoFisher 




Doxycycline-inducible human TRPM2-expressing HEK293 cells (16-18h) were fixed with 
4% paraformaldehyde for 10min on ice, washed in 1xPBS, permeabilized using 0.3% TritonX-
100 dissolved in 1xPBS for 10min at room temperature, and blocked in 4% bovine serum 
albumin overnight at 4°C. Primary antibody (mouse-anti-FLAG, 1:1000, F1804, Sigma, St. Louis 
MO, USA) incubated for 2h at room temperature in 2.5% BSA/PBS and secondary antibody 
(594-conjugated streptavidin, 1:1000, 016-540-084; or 488-donkey-anti-mouse, 1:1000, 715-
545-150; ImmunoResearch Laboratories, West Grove, PA, USA) for 1h at room temperature in 
2.5% BSA/PBS. Then, coverslips were mounted using Prolong Gold Antifade Agent (Thermo 
Fisher Scientific, USA).    
Co-immunoprecipitation 
Protein lysates (500µg) from doxycycline-inducible human TRPM2-expressing HEK293 
cells (16-18h) were incubated for 1h with N-terminal biotin-tagged tatM2NX (20µg) following 
addition of prewashed streptavidin-conjugated agarose (60µl, #16-126, Sigma Aldrich, St. Louis, 
MO, USA) for 1h at 4°C on a rocker. Samples were washed three times with phosphate buffer 
(100mM NaCl, pH 7.4). Purified biotin-tatM2NX complexes with FLAG-TRPM2 were boiled at 
95°C for 5min in Laemmli dye (40-50µl) (BioRad, USA). Bands were resolved using Precast 
Miniprotean gradient gels (4-20% acrylamide, BioRad, USA) cut in half and transferred 50min 
for β-actin and 90min for FLAG-TRPM2 (170kDa) in PVDF membranes (0.22-0.45µm). FLAG-
TRPM2 was probed using mouse anti-FLAG M2 antibody (F1804, Sigma Aldrich, USA) and 
horseradish peroxidase-conjugated goat anti-mouse (1:10000, 115-035-003 or 111-035-003 
ImmunoResearch Laboratories, USA). See Western blot for membrane development. 
Peptide synthesis 
TatM2NX and derivatives were synthetized commercially with >95% purity (Chi 
Scientific, Maynard, MA, USA). All peptides contained cell-permeant N-terminus tat-HIV 
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sequence (YGRKKRRQRRR) fused to the M2NX sequence variations (Table 1). For co-
immunoprecipitation, biotin was conjugated to tatM2NX. 
Electrophysiology 
All recordings were amplified with Axopatch 200B (Axon Instruments, USA), digitized 
with DigiData1550B, and controlled using pClamp10.7 software (Molecular Devices, CA, USA). 
Signals were filtered at 5kHz and digitized at 1kHz. Glass borosilicate electrodes (3.5-5MΩ) 
were used to record human TRPM2 currents activated by +40mV voltage-step from 0mV in 
whole-cell voltage clamp configuration. The protocol was chosen to produce an outward current 
and therefore reduce TRPM2-mediated Ca2+ influx and subsequent cell death. All experiments 
were performed in HEK293 cells (see cell culture section) with HEPES-buffered saline 
containing in mM: 140 NaCl, 2.5 KCl, 10 HEPES, 5 glucose, 1 MgCl2, 1 CaCl, pH 7.4. The 
internal solution contained in mM: 145 K-gluconate, 0.05 EGTA (for physiological buffering of 
Ca2+ at 100-200nM), 1 MgCl2, 10 HEPES, pH 7.3. For antagonism, the internal solution 
contained 100µM ADPR (A0752, Sigma Aldrich, St. Louis, MO, USA) and 0, 0.05, 0.15, 0.3, 0.5, 
2, 5 or 10µM tatM2NX. For competitive antagonism, the internal solution contained 500µM 
ADPR and 0 or 2µM tatM2NX. For SAR experiments, the internal solution contained 100µM 
ADPR and 2µM peptide (tatWV-AA, tat Cterm, tat Nterm). We added clotrimazole (CTZ, 20µM, 
C6019-G, Sigma, St. Louis, MO, USA) after steady-state inhibition as a positive control. 
Exclusion criteria was based on access resistance Ra<15MΩ and remaining leak current 
<350pA after CTZ inhibition. 
Ca2+ imaging 
Live cell imaging of HEK293 cells was performed at room temperature on an Olympus 
IX83 (Olympus Fluoview FV1200 Laser Scanning Confocal Microscope; Olympus Life Science, 
MA, USA) using a 10x objective. For all imaging experiments in this study, controls and peptides 
were tested each experimental day to account for passage differences. All images were 
processed using FIJI Software (Rueden, Schindelin et al. 2017). Each plate was washed 3 
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times with HEPES-buffered saline (see electrophysiology above). A total volume of 2ml was 
added to each plate with 5µM of the Ca2+ indicator Fluo5F, AM (Invitrogen, Eugene, OR, USA), 
with or without 2µM peptide (tatWV-AA, tat Cterm, tat Nterm), or 20µM CTZ and incubated at 
37°C for 40-50min prior to experiments. Then, plates were washed and fresh solution added 
with or without drugs. Excitation illumination was delivered every 10 sec for 20min. After 1min 
baseline, TRPM2 activity was stimulated using 250µM H2O2 and fluorescence recorded for 
20min.   
Methods for studying TRPM2 function in cerebral ischemia  
Experimental models and subject details 
All experimental protocols were approved by the University of Colorado-Denver 
Institutional Animal Care and Use Committee (IACUC) and conformed to the National Institutes 
of Health guidelines for care and use of animals. Adult C57Bl/6 (20-25g) mice (Charles River 
Laboratory) were used for this study. The mice were housed in a standard 12h light and 12h 
dark cycle and had free access to food and water. All experiments in the study adhered to the 
ARRIVE guidelines for animal experiments. Mice were randomly assigned to experimental 
groups and the investigator was blinded as stated below.   
CA/CPR 
Cardiac arrest in 8-12 week old mice was performed as previously described (Deng, 
Yonchek et al. 2014). Briefly, mice were anesthetized using 3% isoflurane and maintained with 
1.5-2% isoflurane in 25% fraction of inspired oxygen (FiO2) via face-mask. Body temperature 
was maintained at 37oC using a heat lamp and heating pad while being monitored with 
temperature probes placed into the left ear canal and rectum. For drug administration, a PE-10 
catheter was inserted into the right internal jugular vein and flushed with heparinized 0.9% 
normal saline solution. Animals were endotracheally intubated using a 24G intravenous catheter 
and connected to a mouse ventilator (Minivent, Hugo Sachs Elektronik, March-Hugstetten, 
Germany) set to a respiratory rate of 160 breaths per minute. Cardiac function was monitored 
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throughout the experiment with electrocardiography (EKG). Cardiac arrest was induced by 
injection of 30μL of 0.5M KCl via the jugular catheter and confirmed by asystole on EKG and 
absence of spontaneous breathing. The endotracheal tube was disconnected from the ventilator 
during cardiac arrest and no spontaneous breathing was observed. During this time anesthesia 
was not being delivered. Body warming was ceased 1min prior to cardiac arrest. During cardiac 
arrest the pericranial temperature was maintained at 37.5±0.5oC by using a water-filled coil.  
Body temperature was allowed to fall spontaneously to 35oC. Resuscitation was begun 8 
minutes after the initiation of cardiac arrest by slow injection of 0.2-0.5mL of epinephrine (16μg 
epinephrine/mL 0.9% saline), chest compressions at a rate of approximately 300 min-1 and 
resumption of ventilation with 100% FiO2 at a rate of 210 breaths/min. Chest compressions were 
stopped upon return of spontaneous circulation (ROSC), defined as electrical evidence of 
cardiac contractions. If ROSC was not achieved within 3min of CPR initiation, resuscitation was 
stopped and the animal was excluded from the study. Five minutes following ROSC, FiO2 was 
decreased to 50%. When the spontaneous respiratory rate was 30breaths/min, the ventilator 
was adjusted to 150breaths/min and when the animals had at least 60spontaneous breaths/min, 
the endotracheal tube was removed. Temperature probes and intravascular catheters were 
removed and the surgical wounds were closed.  
Drug treatment in CA/CPR mice 
For acute neuroprotection experiments, male and female mice were injected with tatSCR 
(20mg/kg) or tatM2NX (20mg/kg) via intravenous (iv) route 30min after sham or CA/CPR 
surgery. For restoration of function experiments, male and female mice were injected with 
tatSCR (20mg/kg) or tatM2NX (20mg/kg) 6 or 29 days after sham or CA/CPR surgery and 
studied on day 7 or 30. 
Histology 
At 3 days after CA/CPR mice were transcardially perfused with 4% paraformaldehyde 
(PFA) and post-fixed in PFA at 4°C overnight. Brains were paraffin embedded and coronal 
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sections containing hippocampus (6μm at 100μm intervals) were cut and stained with 
hematoxylin and eosin (H&E). Staining was visualized with a bright field microscope (Leica 
Microsystems, Buffalo Grove, IL, USA) and analysis of cell morphology was performed 
bilaterally on 3 sections containing anterior hippocampus. Injured CA1 neurons were identified 
by hypereosinophilic cytoplasm and pyknotic nuclei and were presented as a percent of total 
CA1 neurons (% ischemic neurons ± SEM) as previously described (Shimizu, Quillinan et al. 
2016). 
Acute hippocampal slice preparation 
Hippocampal slices were prepared at 7 or 30 days after recovery from CA/CPR or sham 
surgeries. Mice were anesthetized with 3% isoflurane in an O2-enriched chamber. Mice were 
transcardially perfused with ice-cold (2-5oC) oxygenated (95% O2/5% CO2) artificial cerebral 
spinal fluid (aCSF) for 2 minutes prior to decapitation. The brains were then extracted and 
placed in the same aCSF.  The composition of aCSF was the following (in mmol/L): 126 NaCl, 
2.5 KCl, 25 NaHCO3, 1.3 NaH2PO4, 2.5 CaCl2, 1.2 MgCl2 and 12 glucose (Orfila, Shimizu et al. 
2014). Horizontal hippocampal slices (300μm thick) were cut with a Vibratome 1200 (Leica) and 
transferred to a holding chamber containing aCSF for at least 1h before recording. 
Slice electrophysiology 
Synaptically evoked field potentials were recorded from hippocampal CA1 slices that 
were placed on a temperature controlled (31±0.5oC) interface chamber perfused with aCSF at a 
rate of 1.5mL/min. Excitatory post-synaptic potentials (fEPSP) were produced by stimulating the 
Schaffer collaterals (CA3 axons) and recording in the stratum radiatum of the CA1 region. The 
fEPSPs were adjusted to 50% of the maximum slope and test pulses were evoked every 20s. 
Paired pulse responses were recorded using a 50ms interpulse interval (20Hz) and expressed 
as a ratio of the slopes of the second pulse over the first pulse. A 20 min stable baseline was 
established before delivering a theta burst stimulation (TBS) train of four pulses delivered at 
100Hz in 30ms bursts repeated 10 times with 200ms interburst intervals (Orfila, Shimizu et al. 
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2014). Following TBS, the fEPSP was recorded for 60min. The averaged 10 min slope from 50-
60min after TBS was divided by the average of the 10min baseline (set to 100%) prior to TBS to 
determine the amount of potentiation. Analog fEPSPs were amplified (1000X) and filtered 
through a pre-amplifier (Model LP511 AC, Grass Instruments) at 1.0kHz, digitized at 10kHz and 
stored on computer for later off-line analysis (Clampfit 10.4, Axon Instruments). The derivative 
(dV/dT) of the initial fEPSP slope was measured. For time course graphs, normalized fEPSP 
slope values were averaged and plotted as the percent change from baseline. Two 
electrophysiologists (RD and JO) independently verified all LTP results in this report.  
Quantitative RT-PCR 
For quantitative RT-PCR measurement of TRPM2, PARP2 and SIRT2 transcripts, 
hippocampi were harvested at various times after CA/CPR or sham surgeries. Total RNA was 
isolated using the RNAqueous-4 PCR kit (Ambion, Austin, TX, USA) per the manufacturer's 
instructions. Briefly, approximately 1–3 mg of tissue was lysed in lysis buffer and total RNA was 
isolated and eluted from a column with 50μL RNase-free elution buffer, and further treated with 
Turbo DNase (Ambion, Austin, TX, USA,). First strand cDNA was reverse transcribed from 
500ng total RNA with High Capacity cDNA archive Kit (Applied Biosystems, Foster City, CA, 
USA). Real-time PCR reactions using SsoFast PCR mastermix was performed on BioRad CFX 
connect detection system in duplicate using 50ng cDNA. Primers used to detect TRPM2, 
PARP2 and SIRT2 were synthesized by Invitrogen. The housekeeping gene 18s was also 
assayed for each sample using 5ng of cDNA. Cycle parameters used were 95°C for 10min 
followed by 40 cycles of 95°C for 15s and 60°C for 30s. Relative expression levels were 
calculated as the ratio of the target gene to 18S using the normalized ∆∆CT. 
Behavioral test 
The contextual fear conditioning (CFC) paradigm was utilized as a hippocampal-
dependent memory task (Rudy and O'Reilly 2001). The apparatus consisted of two fear-
conditioning chambers with shock grid floors, consisting of 16 stainless steel rods connected to 
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a shock generator (Colbourn Instruments, Model H13-15, Whitehall, PA, USA). Mice were 
transported in white buckets during the training and testing sessions. During training mice were 
allowed to habituate to the conditioning chamber for two separate 2min pre-exposure sessions 
followed by a foot shock (2-s/1.0mA electric shock) immediately after the second exposure. 
Following shock, mice were returned to their home cages. Memory was tested 24h later by 
transporting mice in white buckets and placed back into the fear conditioning chambers. 
Memory was determined by percentage of freezing behavior, measured in 10s intervals across 
a 5min test by a blinded observer and was defined as the absence of movement except for 
heart beat/respiration.  
Western blot methods from brain tissue 
Whole-cell protein lysates were collected from hippocampus and cerebellum of wild-type 
and TRPM2-/- mice (n=2 each) tissue homogenates using neuronal protein extraction reagent 
(Thermo Scientific, Rockford, IL, USA). Protein lysates were centrifuged at 10,000rpm for 10min 
at 4°C and supernatant collected for protein quantification. Protein samples (20µg) were resolved 
using SDS-PAGE, and transferred in PVDF membranes for 90min (n=3, independent Western 
blot experiments). PVDF membranes were blocked in 5% bovine serum albumin for 1hr and 
incubated overnight or 48h at 4°C in primary antibody. TRPM2 expression was assessed with 
rabbit-anti TRPM2 (1:1000, cat# NB110-81601 and NB110-82364 Novus Biologicals, CO, USA), 
rabbit-anti TRPM2 (1:500, cat#GTX112252 Genetex, USA), rabbit-anti TRPM2 (1:1000, 
cat#ARP44380_P050 Aviva Systems San Diego, CA, USA). All membranes were washed 3 times 
followed by 1hr incubation at room temperature in secondary horseradish peroxidase-conjugated 
goat-anti mouse or goat-anti rabbit antibody (1:10000, ImmunoResearch Laboratories, USA). 
Western blot bands were detected using the SuperSignal™ West Femto Maximum 
Sensitivity Substrate (34096, ThermoFisher Scientific, USA) and imaged with BioRad 




For tatM2NX pharmacology 
For analysis of steady-state inhibition of TRPM2 currents, a paired or independent 
samples t-test was performed with statistical significance of p<0.05 for n≥4-10. Potency (IC50) 
was determined using a non-linear regression analysis (Log of inhibitor concentration versus 
normalized response) equation: Y=100/(1+10^((X-LogIC50))); x= log of concentration, 
y=normalized response (current density pA/pF), using Graph Pad Prism version 8.0.2 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. For Ca2+ imaging, 
changes in F/F0 (n=6-12 individual cells/plate) was used to compare groups after normalizing to 
background fluorescence. Individual ROI were drawn for each cell and analyzed using Time 
Series Analyzer plugin in FIJI Software (Rueden, Schindelin et al. 2017). Area under the curve 
for each group was determined and groups were compared to control H2O2 using One-Way 
ANOVA with Dunnett’s post-hoc test for comparison of multiple groups. Statistical significance 
was determined as p<0.05.  
For TRPM2 function in cerebral ischemia 
All data is presented as mean±SEM. Sample size and power analyses were performed 
using previous data generated in our laboratory. To determine group size for LTP recordings, to 
observe a 40% change in LTP between two groups with a standard deviation of 20 and an alpha 
error of 5% and a beta error of 80%, a group of 6 slices per group are required, with no more 
than 2 slices per animal used in analysis per condition. For behavior studies, to observe a 25% 
change in object exploration between two groups with a standard deviation of 15%, with an 
alpha error of 5% and a beta error of 80%, 8 animals per group are require for behavior 
experiments. Statistical analysis was performed using Student’s t-test for two-group 






CONCLUSIONS AND FUTURE DIRECTIONS 
Broad implications 
 The work performed here addresses big questions in the field of cerebral ischemia and 
TRPM2 channels. The studies here demonstrate the mechanism by which TRPM2 activity leads 
to LTP and memory impairment after CA. Furthermore, we characterized and used a novel 
pharmacological inhibitor (tatM2NX) in vivo and in vitro to demonstrate drug efficacy and 
recovery of LTP associated memory deficits in CA mice. We also, unexpectedly, discovered a 
derivative peptide inhibitor (tat Cterm) with similar effects as the parent peptide inhibitor. We 
further described the mechanism of action for these peptides. Overall, this work establishes the 
role of specific proteins activated during pathological conditions that affect the dysfunctional 
hippocampal network.  
Key findings 
 CA mice have impaired LTP and memory 7 and 30 days after injury. This impairment in 
LTP and memory occurs in males and females. Targeting TRPM2 channels at the time of 
reperfusion is neuroprotective only in males, because of TRPM2-mediated cell death in males 
and not females, as described in Chapter III. Inhibiting TRPM2 channels at delayed time points 
(7 days) reverses LTP and memory deficits in both sexes, implicating TRPM2 in suppressing 
synaptic plasticity in cerebral ischemia. Selecting delayed time points provided the ability to 
study cell-death independent mechanisms of TRPM2 temporally focusing on long-term 
alterations in the dysfunctional CA1 hippocampal network and to identify TRPM2-mediated 
activation of GSK3 through CaN. 
 The pharmacology of tatM2NX provides validity to the in vivo CA studies. The peptide 
tatM2NX is a potent antagonist of TRPM2 at the low nanomolar range. This peptide directly 
binds to TRPM2, as predicted using MD, and inhibits GSK3β activation (loss of phosphorylation) 
as quickly as 1h after H2O2-activated oxidative stress. Further, mutagenesis of tatM2NX 
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revealed residues W33 and V34 as critical residues that confer antagonism. The C terminus of 
tatM2NX is sufficient to inhibit TRPM2. It also appears that the peptide tatM2NX is specific for 
TRPM2, as shown by comparison of structures from TRPM4, TRPM7, and TRPM8 denoting 
significant differences in the ligand binding pocket of TRPM2 to other TRPM channels (Figure 
5.1, Table 5.1). The TRPM2 sequence also differs from Transient Receptor Potential Vanilloid 
(TRPV) channels (Table 5.2).  
Remaining questions and future directions 
Neuroprotection versus neuro-restoration  
The field of cerebral ischemia has experienced failure translating preclinical and clinical 
results to effective therapies in humans, discouraging new therapeutic development in cerebral 
ischemia. The standard of care for cardiac arrest to date is the use of hypothermia and a few 
intervention methods to reduce the extent of neuronal death after hypoxic-ischemic injury. 
However, there is no current treatment targeting the preservation or restoration of brain function, 
which include motor, cognitive, memory, and executive functions. Furthermore, the scientific 
community faces challenges of patient stratification, suitable endpoints, undruggable targets, 
and the existent variability between rodent and human physiology (Neuhaus, Couch et al. 
2017). Future studies should incorporate a battery of electrophysiology and behavioral 
measurements to determine the extent of dysfunction, proteins involved, and biomarker 
development.  
Previous studies have focused on TRPM2 inhibition in neuroprotection and acute time 
points after cerebral ischemia in stroke and CA models. The return of spontaneous circulation is 
critical to provide the brain with nutrients and oxygenation required for the high-energy demand. 
However, reperfusion causes tissue stress and damage due to the overload of ions, factors, 
systemic inflammatory signals, and the consequent excessive neuronal excitation. TRPM2 is 
involved in oxidative stress and DND in neurons, particularly in males. Females with TRPM2 
inhibition are not protected and undergo TRPM2-independent cell death. However, our 
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preclinical study shows that males and females similarly engage TRPM2 signaling to regulate 
synaptic plasticity and memory following CA. To our knowledge, this is the first report showing 
TRPM2 contribution to memory deficits in global cerebral ischemia and divergence in TRPM2 
signaling.  
Following neuronal loss through DND, the surviving population of CA1 neurons undergo 
changes in synapses (homeostatic changes) after cerebral ischemia suggesting that these 
neurons are attempting to restore network connectivity (Murphy, Li et al. 2008). We believe that 
novel strategies focusing on targets involved in regulating synaptic plasticity upon injury are 
promising methods for restoration of function. Focusing solely on neuroprotection, despite being 
the goal, may not be ideal to treat an unpredictable injury for which many patients spend hours 
to days before undergoing a complete diagnosis and treatment. TRPM2 is a good biological 
example of a therapeutic target. Inhibition of this channel, if targeted right after reperfusion, is 
neuroprotective. Furthermore, TRPM2 remains chronically active for days to weeks (as we have 
shown in this body of work) and inhibition at time points beyond initial brain injury restores 
hippocampal function and memory deficits in rodents. Future studies should investigate the 
aging population while developing antibody and molecular tools to track TRPM2 localization, 
protein-protein interactions, and signaling pathways in multiple cell-types. There is increasing 
evidence that other cell-types including microglia, astrocytes, endothelial cells, and 
oligodendrocytes play crucial rules in beneficial and detrimental responses to cerebral ischemia 
including changes in morphology, transcriptional signatures, and resilience to injury (Benakis, 
Garcia-Bonilla et al. 2014, Ahrendsen, Grewal et al. 2016). Therefore, pairing basic science 
discoveries to preclinical studies using co-morbidities and systemic responses to injury will 
provide an additional level of complexity that may closely resemble human disease. 
Specificity of TRPM2 antagonists 
TRPM2 inhibitors available to date are mainly small molecules targeting multiple 
proteins. JNJ-28583113 is the most promising TRPM2 pharmacological inhibitor described so 
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far; however, it has limitations crossing the blood brain barrier restricting its use in neurological 
diseases requiring brain penetration. On the other hand, tatM2NX is effective in vivo and shows 
efficacy at the histological, functional and behavioral level in mice. Future studies will require 
studying cell-type specific effects and address the action of tatM2NX in peripheral and/or central 
nervous system. TatN2NX targets TRPM2 in the hippocampus and recovers LTP function as we 
showed in ex vivo brain slices (Chapter III). In the future, conditional TRPM2 genetic ablation in 
combination with tatM2NX treatment will address if TRPM2 inhibition provides beneficial 
cognitive and memory outcomes through multiple brain, vasculature, and immune cell-types. 
Whether TRPM2 mediates cross talk between cell types or intrinsic activation in neurons 
remains to be established.  
The pharmacokinetics of tatM2NX are unknown. The peptide tatM2NX penetrates the 
plasma membrane within 1hr after incubation in cultures and inhibits GSK3β activation by 
TRPM2 (Figure 2.2). However, major difficulties are encountered when injecting mice with 
tatM2NX. Peptide degradation by proteases and other factors as well as the limited tools to 
detect tatM2NX in the brain have hindered our ability to follow peptide kinetics. Future studies 
will utilize a biotin-conjugated tatM2NX to follow pharmacokinetics, tissue penetration, and to 
identify potential tatM2NX targeting of vulnerable populations in different brain regions. 
TatM2NX should readily penetrate the blood brain barrier based on the behavioral data 
presented in this work and previous evidence of other tat peptides reaching the brain. Also, 
tatM2NX brain penetration should increase due to loss of blood brain barrier integrity and 
subsequent leakage following an ischemic insult.   
TRPM2 molecular mechanisms in synaptic plasticity impairment: Is this TRPM2 function 
independent of cell death? 
One of the biggest limitations for the study of TRPM2 channels is the lack of antibody 
specificity (Figure 3.4). Recent cryo-EM structures for TRPM2 revealed complex N- and C-
terminal interactions in the close and ‘primed’ state that upon interactions with ADPR and Ca2+ 
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cause extensive conformational changes to open the channel (Huang, Winkler et al. 2018, 
Wang, Fu et al. 2018). These structural discoveries will move the field towards the development 
of specific antibodies allowing for direct measurements of TRPM2 localization, regulation, co-
interactors and influences in brain networks. Recently, TRPM2 conditional genetic ablation in 
mice allowed for isolation of function (Wu, Indzhykulian et al. 2016). These genetic approaches 
will serve to identify TRPM2 cell-type specific roles in cellular physiology and disease.   
As we showed in this work, TRPM2 sustained activity following CA contributes to LTP 
impairment. Comprehensive studies looking at signaling through CaN and GSK3 and the 
signaling commonalities to Alzheimer’s disease pathways requires further studies. My 
preliminary work suggests that activation of GSK3β, measured as de-phosphorylation at Ser9, 
downstream of TRPM2 at 7 days after CA is not changed compared to sham mice (Figure 5.2). 
These results indicate that either GSK3β is unchanged or activation through Ser9 
phosphorylation is transient and undetectable at 7 days. Moreover, it is possible that TRPM2-
CaN activation of GSK3β is independent of Ser9 phosphorylation. GSK3β inactivation, in certain 
instances, is via Ser389 phosphorylation (Thornton, Pedraza-Alva et al. 2008) while tyrosine 
phosphorylation (Tyr216) represents a more reliable measurement of activity. Also, GSK3β 
activation occurs through changes in post-translational modifications, subcellular localization 
and independent of phosphorylation (Salcedo-Tello, Ortiz-Matamoros et al. 2011). Furthermore, 
GSK3 activity is perpetuated in a positive feedback loop through NMDAR, PP1 and CREB 
signaling during excitotoxicity (Szatmari, Habas et al. 2005), likely occurring in 
neurodegenerative disorders. Future studies will assess if GSK3β activation downstream of 
TRPM2 is neuron-specific and the effects of GSK3β activation on NMDAR. TRPM2 activates 
GSK3β in mammalian cell lines, as shown in Figure 2.4, providing precedence for a common 
signaling pathway. Oxygen-glucose deprivation studies (in vitro ischemia) allows for analysis of 
TRPM2 activity acutely (0-3 days) after OGD. We have preliminary data of decreased GSK3β 
phosphorylation after OGD, but the model also affected total GSK3β protein levels and limited 
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our interpretation of results (Figure 5.3). Also, this approach represents acute time points that 
mainly involve initial oxidative stress, ionic imbalance, and excitotoxicity while lacking systemic 
inflammatory responses and reperfusion, hindering our ability to isolate TRPM2 signaling 
independent of cell death. OGD studies are a reliable approach to look at specific cell-types in 
isolation and molecular signaling indirectly affected by injury at the subcellular level.  
Studying cerebral ischemia requires the selection of models that fit the question of 
interest while keeping in mind the translational significance. Multiple animal models are required 
to validate cerebral ischemia mechanisms in vivo that provide potential translation to humans. 
The number of animals required for preclinical studies and considerable heterogeneity among 
animals make consistency of results from molecular experiments difficult. Also, study end-points 
and quality of the studies reported should follow the Stroke Academic Industry Roundtable to 
provide consistent preclinical results (Neuhaus, Couch et al. 2017). In the clinical setting, the 
timing from onset to treatment limits the therapeutic window. Therefore, animal models should 
also focus on later time points and potential targets suitable for clinical intervention. More 
studies looking at cell-type specific ‘omics’ (genetic, transcriptional, and proteomics) changes 
after cerebral ischemia are critical to identify targetable mechanisms and biomarkers of disease 










Figure 5.1 Structure of TRPM family members. Comparison between the tertiary 
structures of human TRPM2 (orange), human TRPM4 (blue), mouse TRPM7 (green), and 
TRPM8 (magenta) (PDB IDs: 6MIX, 6BQR, 5ZX5, and 6NR4, respectively). Arrow indicates 
the proposed binding site for tatMXN2, which is not present in the other family members. 







Figure 5.2 GSK3 activation following CA/CPR. A)  CA1 hippocampal lysates from 
control (Ct), sham (Sh) or CA/CPR (CA) animals treated with the CaN inhibitor FK-506 
(FK). Each lane represents n=1 (animal), total n=3-7 per condition, n=1-2 for controls. 
B) CA1 hippocampal slices from sham or CA/CPR (CA) treated with ACSF or 
combination (CsA+FK-506, 2µM). Each lane represents n=1 animal, n=3-4 per group. 
C) CA1 hippocampal slices from sham or CA/CPR (CA) treated with ACSF or TRPM2 




















Table 5.1 TRPM2 sequence alignment to TRPM channels 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 
SP|O94759|TRPM2_HUMAN MEPSALRKAGSEQEEGFEGLPRRV------TDLGMVSNL---RRSNSSLFKSWRLQCPFG 51 
SP|Q7Z4N2|TRPM1_HUMAN ------------------------------------------------------------ 
SP|Q9HCF6|TRPM3_HUMAN -MPEP---WGT---VYFLGIAQVFSFLFSWWNLEGVMNQ---ADAPRPLNWTIRKLCHAA 50 
SP|Q8TD43|TRPM4_HUMAN ------------------------------------------------------------ 
SP|Q9NZQ8|TRPM5_HUMAN ------------------------------------------------------------ 
SP|Q9BX84|TRPM6_HUMAN ----------------------------------------------------------MK 2 
SP|Q96QT4|TRPM7_HUMAN ------------------------------------------------------------ 
SP|Q7Z2W7|TRPM8_HUMAN -------------------MSFRA------ARLSMRNRRNDTLDSTRTLYSSASRS--TD 33 
                                                                                   
 
SP|O94759|TRPM2_HUMAN N---NDKQESLSSWIPENIKKKECVYFVESSKLSDAGKV---------VCQCGYTHEQHL 99 
SP|Q7Z4N2|TRPM1_HUMAN ------------------------------MKDSNRC-------------CCGQFTNQHI 17 
SP|Q9HCF6|TRPM3_HUMAN FLPSVRLLKAQKSWIERAFYKRECVHIIPSTKDPHRC-------------CCGRLIGQHV 97 
SP|Q8TD43|TRPM4_HUMAN ----MVVPEKEQSWIPKIFKKKTCTTFIVDST--DPGGT---------LCQCGRPRTAHP 45 
SP|Q9NZQ8|TRPM5_HUMAN ------------------------------------------------------------ 
SP|Q9BX84|TRPM6_HUMAN EQPVLERLQSQKSWIKGVFDKRECSTIIPSSKNPHRCTPVCQVCQNLIRCYCGRLIGDHA 62 
SP|Q96QT4|TRPM7_HUMAN --------MSQKSWIESTLTKRECVYIIPSSKDPHRCLPGCQICQQLVRCFCGRLVKQHA 52 
SP|Q7Z2W7|TRPM8_HUMAN L---SYSESDLVNFIQANFKKRECVFFTKDSK---ATEN---------VCKCGYAQSQHM 78 
                                                                                   
 
SP|O94759|TRPM2_HUMAN EEATK--------------PHTFQGTQWDPKKHVQEMPTDAFGDIVFTGLSQ-KVKKYVR 144 
SP|Q7Z4N2|TRPM1_HUMAN PPLPSATPSKN---EEESKQVETQPEKWSVAKHTQSYPTDSYGVLEFQGGGYSNKAMYIR 74 
SP|Q9HCF6|TRPM3_HUMAN GLTPSISVLQNEKNESRLSRNDIQSEKWSISKHTQLSPTDAFGTIEFQGGGHSNKAMYVR 157 
SP|Q8TD43|TRPM4_HUMAN AVAME------------DAFGAAVVTVWDSDAHTTEKPTDAYGELDFTGAGR-KHSNFLR 92 
SP|Q9NZQ8|TRPM5_HUMAN ---MQ------------DVQGPRPGS--PGDAEDRRELGLHRGEVNFGGSGK-KRGKFVR 42 
SP|Q9BX84|TRPM6_HUMAN GIDYSWTIS---------AAKGKESEQWSVEKHTTKSPTDTFGTINFQDGEHTHHAKYIR 113 
SP|Q96QT4|TRPM7_HUMAN CFTASLAMKYSDVKL--GDHFNQAIEEWSVEKHTEQSPTDAYGVINFQGGSHSYRAKYVR 110 
SP|Q7Z2W7|TRPM8_HUMAN EGTQ-----------------INQSEKWNYKKHTKEFPTDAFGDIQFETLGK-K-GKYIR 119 
                                                      .         * : *          ::* 
 
SP|O94759|TRPM2_HUMAN VSQDTPSSVIYHLMTQHWGLDVPNLLISVTGGAKNFNMKPRLKSIFRRGLVKVAQTTGAW 204 
SP|Q7Z4N2|TRPM1_HUMAN VSYDTKPDSLLHLMVKDWQLELPKLLISVHGGLQNFEMQPKLKQVFGKGLIKAAMTTGAW 134 
SP|Q9HCF6|TRPM3_HUMAN VSFDTKPDLLLHLMTKEWQLELPKLLISVHGGLQNFELQPKLKQVFGKGLIKAAMTTGAW 217 
SP|Q8TD43|TRPM4_HUMAN LSDRTDPAAVYSLVTRTWGFRAPNLVVSVLGGSGGPVLQTWLQDLLRRGLVRAAQSTGAW 152 
SP|Q9NZQ8|TRPM5_HUMAN VPSGVAPSVLFDLLLAEWHLPAPNLVVSLVGEEQPFAMKSWLRDVLRKGLVKAAQSTGAW 102 
SP|Q9BX84|TRPM6_HUMAN TSYDTKLDHLLHLMLKEWKMELPKLVISVHGGIQNFTMPSKFKEIFSQGLVKAAETTGAW 173 
SP|Q96QT4|TRPM7_HUMAN LSYDTKPEVILQLLLKEWQMELPKLVISVHGGMQKFELHPRIKQLLGKGLIKAAVTTGAW 170 
SP|Q7Z2W7|TRPM8_HUMAN LSCDTDAEILYELLTQHWHLKTPNLVISVTGGAKNFALKPRMRKIFSR-LIYIAQSKGAW 178 
                          .    :  *:   * :  *:*::*: *      :   ::.:: : *:  * :.*** 
 
SP|O94759|TRPM2_HUMAN IITGGSHTGVMKQVGEAVRDFSLSSSYKEGELITIGVATWGTVHRREGLIH---PTGSFP 261 
SP|Q7Z4N2|TRPM1_HUMAN IFTGGVSTGVISHVGDALKDHSSKSR---GRVCAIGIAPWGIVENKEDLVGK-----DVT 186 
SP|Q9HCF6|TRPM3_HUMAN IFTGGVNTGVIRHVGDALKDHASKSR---GKICTIGIAPWGIVENQEDLIGR-----DVV 269 
SP|Q8TD43|TRPM4_HUMAN IVTGGLHTGIGRHVGVAVRDHQMASTGG-TKVVAMGVAPWGVVRNRDTLIN---PKGSFP 208 
SP|Q9NZQ8|TRPM5_HUMAN ILTSALRVGLARHVGQAVRDHSLASTSTKVRVVAVGMASLGRVLHRRILEE---AQEDFP 159 
SP|Q9BX84|TRPM6_HUMAN IITEGINTGVSKHVGDALKSHSSHSL---RKIWTVGIPPWGVIENQRDLIGK-----DVV 225 
SP|Q96QT4|TRPM7_HUMAN ILTGGVNTGVAKHVGDALKEHASRSS---RKICTIGIAPWGVIENRNDLVGR-----DVV 222 
SP|Q7Z2W7|TRPM8_HUMAN ILTGGTHYGLMKYIGEVVRDNTISRSS-EENIVAIGIAAWGMVSNRDTLIRNCDAEGYFL 237 
                      *.* .   *:   :* .::.          .: ::*:   * : .:  *         .  
 
SP|O94759|TRPM2_HUMAN AEYILDEDG-QGNLTCLDSNHSHFILVDDGTHGQYGVEIPLRTRLEKFISEQTKERG--- 317 
SP|Q7Z4N2|TRPM1_HUMAN RVYQTMSNP-LSKLSVLNNSHTHFILADNGTLGKYGAEVKLRRLLEKHISLQKINTR--- 242 
SP|Q9HCF6|TRPM3_HUMAN RPYQTMSNP-MSKLTVLNSMHSHFILADNGTTGKYGAEVKLRRQLEKHISLQKINTRCLP 328 
SP|Q8TD43|TRPM4_HUMAN ARYRWRGDPEDGVQFPLDYNYSAFFLVDDGTHGCLGGENRFRLRLESYISQQKTGVG--- 265 
SP|Q9NZQ8|TRPM5_HUMAN VHYPEDDGGSQGPLCSLDSNLSHFILVEPGPPGKGDGLTELRLRLEKHISEQRAGYG--- 216 
SP|Q9BX84|TRPM6_HUMAN CLYQTLDNP-LSKLTTLNSMHSHFILSDDGTVGKYGNEMKLRRNLEKYLSLQKIHCR--- 281 
SP|Q96QT4|TRPM7_HUMAN APYQTLLNP-LSKLNVLNNLHSHFILVDDGTVGKYGAEVRLRRELEKTINQQRIHAR--- 278 
SP|Q7Z2W7|TRPM8_HUMAN AQYLMDDFT-RDPLYILDNNHTHLLLVDNGCHGHPTVEAKLRNQLEKYISERTIQDS--- 293 
                        *        .    *:   : ::* : *  *       :*  **. :. :         
 
SP|O94759|TRPM2_HUMAN ---------------------GVA-IKIPIVCVVLEGGPGTLHTIDNATTNG--TPCVVV 353 
SP|Q7Z4N2|TRPM1_HUMAN ----------------------LG-QGVPLVGLVVEGGPNVVSIVLEYLQEEPPIPVVIC 279 
SP|Q9HCF6|TRPM3_HUMAN FFSLDSRLFYSFWGSCQLDSVGIG-QGVPVVALIVEGGPNVISIVLEYLRDTPPVPVVVC 387 
SP|Q8TD43|TRPM4_HUMAN ---------------------GTG-IDIPVLLLLIDGDEKMLTRIENATQAQ--LPCLLV 301 
SP|Q9NZQ8|TRPM5_HUMAN ---------------------GTGSIEIPVLCLLVNGDPNTLERISRAVEQA--APWLIL 253 
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SP|Q9BX84|TRPM6_HUMAN ----------------------SR-QGVPVVGLVVEGGPNVILSVWETVKDK--DPVVVC 316 
SP|Q96QT4|TRPM7_HUMAN ----------------------IG-QGVPVVALIFEGGPNVILTVLEYLQESPPVPVVVC 315 
SP|Q7Z2W7|TRPM8_HUMAN ---------------------NYG-GKIPIVCFAQGGGKETLKAINTSIKNK--IPCVVV 329 
                                                 :*:: .   *.   :  :          * ::  
 
SP|O94759|TRPM2_HUMAN EGSGRVADVIAQVANLPVSDIT-ISLIQQKLSVFFQEMFETFTESRIVEWTKKIQDIVRR 412 
SP|Q7Z4N2|TRPM1_HUMAN DGSGRASDILSFAHKYCEEGGIINESLREQLLVTIQKTFN-YNKAQSHQLFAIIMECMKK 338 
SP|Q9HCF6|TRPM3_HUMAN DGSGRASDILAFGHKYSEEGGLINESLRDQLLVTIQKTFT-YTRTQAQHLFIILMECMKK 446 
SP|Q8TD43|TRPM4_HUMAN AGSGGAADCLAETLEDTLAPGS-GGARQGEARDRI---RRFFPKGDLEVLQAQVERIMTR 357 
SP|Q9NZQ8|TRPM5_HUMAN VGSGGIADVLAALVNQPHLLVP-KVAEKQFKEKFP---SKHFSWEDIVRWTKLLQNITSH 309 
SP|Q9BX84|TRPM6_HUMAN EGTGRAADLLAFTHKHLADEGMLRPQVKEEIICMIQNTFN-FSLKQSKHLFQILMECMVH 375 
SP|Q96QT4|TRPM7_HUMAN EGTGRAADLLAYIHKQTEEGGNLPDAAEPDIISTIKKTFN-FGQNEALHLFQTLMECMKR 374 
SP|Q7Z2W7|TRPM8_HUMAN EGSGQIADVIASLVEVED-ALT-SSAVKEKLVRFLPRTVSRLPEEETESWIKWLKEILEC 387 
                       *:*  :* ::   :            .                         :       
 
SP|O94759|TRPM2_HUMAN RQLLTVFREGKDGQQDVDVAILQALLKASRSQDHFGHENWDHQLKLAVAWNRVDIARSEI 472 
SP|Q7Z4N2|TRPM1_HUMAN KELVTVFRMGSEGQQDIEMAILTALLKGTNVS-------APDQLSLALAWNRVDIARSQI 391 
SP|Q9HCF6|TRPM3_HUMAN KELITVFRMGSEGHQDIDLAILTALLKGANAS-------APDQLSLALAWNRVDIARSQI 499 
SP|Q8TD43|TRPM4_HUMAN KELLTVYSS-EDGSEEFETIVLKALVKACGSS---EASAYLDELRLAVAWNRVDIAQSEL 413 
SP|Q9NZQ8|TRPM5_HUMAN QHLLTVYDFEQEGSEELDTVILKALVKACKSHSQ-EPQDYLDELKLAVAWDRVDIAKSEI 368 
SP|Q9BX84|TRPM6_HUMAN RDCITIFDADSEEQQDLDLAILTALLKGTNLS-------ASEQLNLAMAWDRVDIAKKHI 428 
SP|Q96QT4|TRPM7_HUMAN KELITVFHIGSDEHQDIDVAILTALLKGTNAS-------AFDQLILTLAWDRVDIAKNHV 427 
SP|Q7Z2W7|TRPM8_HUMAN SHLLTVIKMEEAGDEIVSNAISYALYKAF-STSEQDKDNWNGQLKLLLEWNQLDLANDEI 446 
                       . :*:    .   : ..  :  ** *.              :* * : *:::*:*...: 
 
SP|O94759|TRPM2_HUMAN FMDEWQWKP--------------------------------------------------- 481 
SP|Q7Z4N2|TRPM1_HUMAN FVFGPHWPPLGSLAPPTDSKATEKEKKPPMATTKGGRGKGKGKKKGKVKEEVEEETDPRK 451 
SP|Q9HCF6|TRPM3_HUMAN FIYGQQWPV--------------------------------------------------- 508 
SP|Q8TD43|TRPM4_HUMAN FRGDIQWRS--------------------------------------------------- 422 
SP|Q9NZQ8|TRPM5_HUMAN FNGDVEWKS--------------------------------------------------- 377 
SP|Q9BX84|TRPM6_HUMAN LIYEQHWKP--------------------------------------------------- 437 
SP|Q96QT4|TRPM7_HUMAN FVYGQQWLV--------------------------------------------------- 436 
SP|Q7Z2W7|TRPM8_HUMAN FTNDRRWES--------------------------------------------------- 455 
                      :    .*                                                      
 
SP|O94759|TRPM2_HUMAN -------SDLHPTMTAALISNKPEFVKLFLENGVQLKEFVTWDTLLYLYENL--DPSCLF 532 
SP|Q7Z4N2|TRPM1_HUMAN IELLNWVNALEQAMLDALVLDRVDFVKLLIENGVNMQHFLTIPRLEELYNTRLGPPNT-L 510 
SP|Q9HCF6|TRPM3_HUMAN -------GSLEQAMLDALVLDRVDFVKLLIENGVSMHRFLTISRLEELYNTRHGPSNT-L 560 
SP|Q8TD43|TRPM4_HUMAN -------FHLEASLMDALLNDRPEFVRLLISHGLSLGHFLTPMRLAQLYSAA--PSNSLI 473 
SP|Q9NZQ8|TRPM5_HUMAN -------CDLEEVMVDALVSNKPEFVRLFVDNGADVADFLTYGRLQELYRSV--SRKSLL 428 
SP|Q9BX84|TRPM6_HUMAN -------DALEQAMSDALVMDRVDFVKLLIEYGVNLHRFLTIPRLEELYNTKQGPTNTLL 490 
SP|Q96QT4|TRPM7_HUMAN -------GSLEQAMLDALVMDRVAFVKLLIENGVSMHKFLTIPRLEELYNTKQGPTNPML 489 
SP|Q7Z2W7|TRPM8_HUMAN -------ADLQEVMFTALIKDRPKFVRLFLENGLNLRKFLTHDVLTELFSNH--FSTLVY 506 
                               *.  :  **: ::  **:*::. * .:  *:*   *  *:       .    
 
SP|O94759|TRPM2_HUMAN HSKLQKVLVEDPE-RPA--------CAPAAPRLQMHHVAQVLRELLGDFTQPLYPRPRHN 583 
SP|Q7Z4N2|TRPM1_HUMAN HLLVRDVKKSN---------------LPPDYHISLIDIGLVLEYLMGGAYRCNYTRKNFR 555 
SP|Q9HCF6|TRPM3_HUMAN YHLVRDVKKGN---------------LPPDYRISLIDIGLVIEYLMGGAYRCNYTRKRFR 605 
SP|Q8TD43|TRPM4_HUMAN RNLLDQASHSAGTKAPAL--------KGGAAELRPPDVGHVLRMLLGKMCAPRYPSGGAW 525 
SP|Q9NZQ8|TRPM5_HUMAN FDLLQRKQEEARLTLAGLGTQQAREPPAGPPAFSLHEVSRVLKDFLQDACRGFYQDGRPG 488 
SP|Q9BX84|TRPM6_HUMAN HHLVQDVKQHT---------------LLSGYRITLIDIGLVVEYLIGRAYRSNYTRKHFR 535 
SP|Q96QT4|TRPM7_HUMAN FHLVRDVKQGN---------------LPPGYKITLIDIGLVIEYLMGGTYRCTYTRKRFR 534 
SP|Q7Z2W7|TRPM8_HUMAN RNLQ-IA--KN-----S--------YN--------DALLTFVWKLVANFRRGFRKEDR-N 541 
                                                           :  .:  ::               
 
SP|O94759|TRPM2_HUMAN DRLRLLLPV-------------------------------------------PHVKLNVQ 600 
SP|Q7Z4N2|TRPM1_HUMAN TLYNNLFGPKRPKALKLL-------------GMEDD--------------EPPAK----G 584 
SP|Q9HCF6|TRPM3_HUMAN TLYHNLFGPKRPKALKLL-------------GMEDD--------------IPLRR----G 634 
SP|Q8TD43|TRPM4_HUMAN DPHPGQ-------------------------------------------------GFGES 536 
SP|Q9NZQ8|TRPM5_HUMAN DRRRAEKGP-------------------------------------------AK-RPTGQ 504 
SP|Q9BX84|TRPM6_HUMAN ALYNNLYRKYK--------------HQRHSSGNRNESAESTLHSQFIRTAQPYKFKEKSI 581 
SP|Q96QT4|TRPM7_HUMAN LIYNSLGGNNRRSGRNTSSSTPQLRKSHESFGNRADKKEKMRHNHFIKTAQPYRPKIDTV 594 
SP|Q7Z2W7|TRPM8_HUMAN GRDEM------------------------------------------------------- 546 
                                                                                   
 
SP|O94759|TRPM2_HUMAN G-VSLRSLYKR---SSG--HVTFTMDPIRDLLIWAIVQNRRELAGIIWAQSQDCIAAALA 654 
SP|Q7Z4N2|TRPM1_HUMAN KKKKKKKKEEEIDIDVDDPAVSRFQYPFHELMVWAVLMKRQKMAVFLWQRGEESMAKALV 644 
SP|Q9HCF6|TRPM3_HUMAN RKT-TKKREEEVDIDLDDPEINHFPFPFHELMVWAVLMKRQKMALFFWQHGEEAMAKALV 693 
SP|Q8TD43|TRPM4_HUMAN MYLLSDKATSP---LSL--DAGLGQAPWSDLLLWALLLNRAQMAMYFWEMGSNAVSSALG 591 
SP|Q9NZQ8|TRPM5_HUMAN KWLL------------D--LNQKSENPWRDLFLWAVLQNRHEMATYFWAMGQEGVAAALA 550 
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SP|Q9BX84|TRPM6_HUMAN VLHKSRKKSKE-QNVSDDPESTGFLYPYNDLLVWAVLMKRQKMAMFFWQHGEEATVKAVI 640 
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SP|Q7Z2W7|TRPM8_HUMAN ------------------------------------------------------------ 







SP|Q9BX84|TRPM6_HUMAN LLVLDLQGVGENLTDPSVIKPEVKQSRGMVFGPANLGEDAIRNFIAKHHCNSCCRKLKLP 1978 
SP|Q96QT4|TRPM7_HUMAN LLVLDLQGVGENLTDPSVIKAEEKRSCDMVFGPANLGEDAIKNFRAKHHCNSCCRKLKLP 1822 
SP|Q7Z2W7|TRPM8_HUMAN ------------------------------------------------------------ 







SP|Q9BX84|TRPM6_HUMAN DLKRNDYSPERINSTFGLEIKIESAEEPPARETGRNSPEDDMQL-- 2022 
SP|Q96QT4|TRPM7_HUMAN DLKRNDYTPDKIIFPQDEPSDLNL---QPGNSTKESESTNSVRLML 1865 
SP|Q7Z2W7|TRPM8_HUMAN ---------------------------------------------- 









Table 5.2 TRPM2 sequence alignment to Transient Receptor Potential Vallinoid (TRPV) 
channels 
 
CLUSTAL O(1.2.4) multiple sequence alignment 
 





SP|Q8NER1|TRPV1_HUMAN ----------------------------------------------------------MK 2 
SP|Q9Y5S1|TRPV2_HUMAN ----------------------------------------------------------MT 2 
                                                                                   
 
SP|O94759|TRPM2_HUMAN SWIPENIKKKECVYFVESSKLSDAGKVVCQCGYTHEQHLEEATKPHTFQGTQWDPKKHVQ 120 
SP|Q9HBA0|TRPV4_HUMAN -MAD------------------------------------------SSEGPRAGPGEV-A 16 
SP|Q8NET8|TRPV3_HUMAN --------------------------------------------------MKAHPKEM-V 9 
SP|Q9H1D0|TRPV6_HUMAN ------------------------------------------------------------ 
SP|Q9NQA5|TRPV5_HUMAN ------------------------------------------------------------ 
SP|Q8NER1|TRPV1_HUMAN KWSS------------------------------------------TDLGAAADPLQK-D 19 
SP|Q9Y5S1|TRPV2_HUMAN -------------------------------------------------SPSSSPVF--- 10 
                                                                                   
 
SP|O94759|TRPM2_HUMAN EMPTDAFGDIVFTGLSQKVKKYVRVSQDTPSSVIY------HLMTQHWGLDVPNLLISVT 174 
SP|Q9HBA0|TRPV4_HUMAN ELPGDE--------------------SGTPGGEAFPLSSLANLFEGEDGSLSP---SPAD 53 
SP|Q8NET8|TRPV3_HUMAN PLMGKR--------------------VAAPSGNPAI----------------------LP 27 
SP|Q9H1D0|TRPV6_HUMAN --------------------------------------------------MGP---LQGD 7 
SP|Q9NQA5|TRPV5_HUMAN ------------------------------------------------------------ 
SP|Q8NER1|TRPV1_HUMAN T--------------------------------------------------CP---DPLD 26 
SP|Q9Y5S1|TRPV2_HUMAN ---------------------------------------------------RL---ETLD 16 
                                                                                   
 
SP|O94759|TRPM2_HUMAN GG--AKNFNMKPRLKSIFRRGLVKVAQTTGAWIITGGSHTGVMKQVGEAVRDFSLSSSYK 232 
SP|Q9HBA0|TRPV4_HUMAN ASRPAGPGDGRPNLRMKFQ----------------------------------------- 72 
SP|Q8NET8|TRPV3_HUMAN E---KRPAEITPTKKSAHF----------------------------------------- 43 
SP|Q9H1D0|TRPV6_HUMAN GGPALGGADVAPRLSPVRVWPRPQAPKE-------------------------------- 35 
SP|Q9NQA5|TRPV5_HUMAN ------------------------------------------------------------ 
SP|Q8NER1|TRPV1_HUMAN GDPNSRPPPAKPQLSTAKSR---------------------------------------- 46 
SP|Q9Y5S1|TRPV2_HUMAN GGQEDGSE--------ADRG---------------------------------------- 28 
                                                                                   
 
SP|O94759|TRPM2_HUMAN EGELITIGVATWGTVHRREGLIHPTGSFPAEYILDEDGQGNLTCLDSNHSHFILVDDGTH 292 
SP|Q9HBA0|TRPV4_HUMAN ------------------------------------------------------------ 
SP|Q8NET8|TRPV3_HUMAN -----------------------------------------------------------F 44 
SP|Q9H1D0|TRPV6_HUMAN -------------------P--------------------------------------AL 38 
SP|Q9NQA5|TRPV5_HUMAN ------------------------------------------------------------ 
SP|Q8NER1|TRPV1_HUMAN -----------------------------------------------------------T 47 
SP|Q9Y5S1|TRPV2_HUMAN -----------------------------------------------------------K 29 
                                                                                   
 
SP|O94759|TRPM2_HUMAN GQYGVEIPLRTRLEKFISEQTKERGGVAIKIPIVCVVLEGGPGTLHTIDNATTNGTPCVV 352 
SP|Q9HBA0|TRPV4_HUMAN GAFRKGVPNPIDLLESTLYESS-VVPGPKKAPMDSLFDYGTYRHHSSD------------ 119 
SP|Q8NET8|TRPV3_HUMAN LEIEGFEPNPT--------VAK-TSPPVFSKPMDSNIRQCISGNCDDM------------ 83 
SP|Q9H1D0|TRPV6_HUMAN HPMGLSLPKEK-------------------GLILCLW----SKFCRW------------- 62 
SP|Q9NQA5|TRPV5_HUMAN --MGGFLPKAE-------------------GPGSQLQ----KLLPSF------------- 22 
SP|Q8NER1|TRPV1_HUMAN RLFGKGDSEEA-------------------FPVDCPHEEGELDSCPTITVS-----P--- 80 
SP|Q9Y5S1|TRPV2_HUMAN LDFGSGLP-----------------------PMESQFQGEDRKFAPQIRVN-----L--- 58 
                                                                                   
 
SP|O94759|TRPM2_HUMAN VEGSGRVADVIA----QVANLPVSDITISLIQQKLSVF-FQEMFETFTESRIVE------ 401 
SP|Q9HBA0|TRPV4_HUMAN ---NKRWRKKIIEKQPQSPKAPAPQ-----PPPILKVFNRPILFDIVSRGSTADLDGLLP 171 
SP|Q8NET8|TRPV3_HUMAN -DSPQSPQDDVT-ETPSNPNSPSAQLAKE-EQRRKKRRLKKRIFAAVSEGCVEELVELLV 140 
SP|Q9H1D0|TRPV6_HUMAN FQRRESWAQSRDEQNLL----------------QQKRIWESPLLLAAKDNDVQALNKLLK 106 
SP|Q9NQA5|TRPV5_HUMAN LVREQDWDQHLDKLHML----------------QQKRILESPLLRASKENDLSVLRQLLL 66 
SP|Q8NER1|TRPV1_HUMAN VITIQRPGDGPTGARLLSQDSVAAS-----TEKTLRLYDRRSIFEAVAQNNCQDLESLLL 135 
SP|Q9Y5S1|TRPV2_HUMAN ---NYRKG--------------TGA-----SQPDPNRFDRDRLFNAVSRGVPEDLAGLPE 96 
                                                                ::     .           
 
SP|O94759|TRPM2_HUMAN ----WTKKIQDIVRRRQLLTVFREGKDGQQDVDVAILQ----------ALLKASRSQ--- 444 
94 
 
SP|Q9HBA0|TRPV4_HUMAN FLLTHKKRLTDE--------EFREPSTGKTCLPKALLNLSNGRNDTIPVLLDIAERTGNM 223 
SP|Q8NET8|TRPV3_HUMAN ELQELCRRRHDEDVPDFLMHKLTASDTGKTCLMKALLNINPNTKEIVRILLAFAEENDIL 200 
SP|Q9H1D0|TRPV6_HUMAN YE--DCK-------------VHQRGAMGETALHIAALY--DNLEAA-MVLM------EAA 142 
SP|Q9NQA5|TRPV5_HUMAN DC--TCD-------------VRQRGALGETALHIAALY--DNLEAA-LVLM------EAA 102 
SP|Q8NER1|TRPV1_HUMAN FLQKSKKHLTDN--------EFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEIARQTDSL 187 
SP|Q9Y5S1|TRPV2_HUMAN YLSKTSKYLTDS--------EYTEGSTGKTCLMKAVLNLKDGVNACILPLLQIDRDSGNP 148 
                                                 *:  :  * *            *:          
 
SP|O94759|TRPM2_HUMAN -----DHFGHENWDHQLKLAVAWNRVDIARSEIFMDEWQWKPSDLHPTMTAALISNKPEF 499 
SP|Q9HBA0|TRPV4_HUMAN REFINSPFRDIYYRGQTA------------------------------LHIAIERRCKHY 253 
SP|Q8NET8|TRPV3_HUMAN GRFINAEYTEEAYEGQTA------------------------------LNIAIERRQGDI 230 
SP|Q9H1D0|TRPV6_HUMAN PELVFEPMTSELYEGQTA------------------------------LHIAVVNQNMNL 172 
SP|Q9NQA5|TRPV5_HUMAN PELVFEPTTCEAFAGQTA------------------------------LHIAVVNQNVNL 132 
SP|Q8NER1|TRPV1_HUMAN KELVNASYTDSYYKGQTA------------------------------LHIAIERRNMAL 217 
SP|Q9Y5S1|TRPV2_HUMAN QPLVNAQCTDDYYRGHSA------------------------------LHIAIEKRSLQC 178 
                                  :  :                                :  *:  .     
 
SP|O94759|TRPM2_HUMAN VKLFLENGVQLKEFVTWDTL------LYLYENL----DPSCLFHSKLQKVLVEDPERPAC 549 
SP|Q9HBA0|TRPV4_HUMAN VELLVAQGADVHAQARGRFFQPKDEGGYFYFGELPLSLAACTNQPHIVNYLTENPHKKAD 313 
SP|Q8NET8|TRPV3_HUMAN AALLIAAGADVNAHAKGAFFNPKYQHEGFYFGETPLALAACTNQPEIVQLLME--HEQTD 288 
SP|Q9H1D0|TRPV6_HUMAN VRALLARRASVSARATGTAFRRSPC-NLIYFGEHPLSFAACVNSEEIVRLLIE---HGAD 228 
SP|Q9NQA5|TRPV5_HUMAN VRALLTRRASVSARATGTAFRRSPR-NLIYFGEHPLSFAACVNSEEIVRLLIE---HGAD 188 
SP|Q8NER1|TRPV1_HUMAN VTLLVENGADVQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTAD 277 
SP|Q9Y5S1|TRPV2_HUMAN VKLLVENGANVHARACGRFFQKGQG-TCFYFGELPLSLAACTKQWDVVSYLLENPHQPAS 237 
                      .  ::   ..:   .    :        :* .       :*     :   * :   . :  
 
SP|O94759|TRPM2_HUMAN APAAPRLQ---MHH--------------VAQVLRELL-----GDFTQPLYPRPRHNDRLR 587 
SP|Q9HBA0|TRPV4_HUMAN MRRQDSRGNTVLHALVAIADNTRENTKFVTKMYDLLLLKCARLFPDSNLEAVLNNDGLSP 373 
SP|Q8NET8|TRPV3_HUMAN ITSRDSRGNNILHALVTVAEDFKTQNDFVKRMYDMILLRSGN----WELETTRNNDGLTP 344 
SP|Q9H1D0|TRPV6_HUMAN IRAQDSLGNTVLHILILQ-----PNKTFACQMYNLLLSYDRHGDHLQPLDLVPNHQGLTP 283 
SP|Q9NQA5|TRPV5_HUMAN IRAQDSLGNTVLHILILQ-----PNKTFACQMYNLLLSYDGHGDHLQPLDLVPNHQGLTP 243 
SP|Q8NER1|TRPV1_HUMAN ISARDSVGNTVLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTP 337 
SP|Q9Y5S1|TRPV2_HUMAN LQATDSQGNTVLHALVMISDNSAENIALVTSMYDGLLQAGARLCPTVQLEDIRNLQDLTP 297 
                                 :*               .  :   :*           *    . ..    
 
SP|O94759|TRPM2_HUMAN LLLPVPHVKLNVQGVSL-R-----SLYKRSSGHVTFTMDPIRDLLIWAIVQNRRELAGII 641 
SP|Q9HBA0|TRPV4_HUMAN LMMAAKTGKIGIFQHIIRREVTDEDTRHLSRKFKDWAYGPVYSSL--------------- 418 
SP|Q8NET8|TRPV3_HUMAN LQLAAKMGKAEILKYILSREIKEKRLRSLSRKFTDWAYGPVSSSL--------------- 389 
SP|Q9H1D0|TRPV6_HUMAN FKLAGVEGNTVMFQHLMQK-----------RKHTQWTYGPLTSTL--------------- 317 
SP|Q9NQA5|TRPV5_HUMAN FKLAGVEGNTVMFQHLMQK-----------RRHIQWTYGPLTSIL--------------- 277 
SP|Q8NER1|TRPV1_HUMAN LALAAGTGKIGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSL--------------- 382 
SP|Q9Y5S1|TRPV2_HUMAN LKLAAKEGKIEIFRHILQREFS--GLSHLSRKFTEWCYGPVRVSL--------------- 340 
                      : :     :  :    : :             .  :  .*:   *                
 
SP|O94759|TRPM2_HUMAN WAQSQDCIAAALACSKILKELSKEEEDTDSSEEMLALAEEYEHRAIGVFTECYRKDEERA 701 
SP|Q9HBA0|TRPV4_HUMAN ------------------YDLSS----LDTCGEEASVL------EILVYN-S-K-IENRH 447 
SP|Q8NET8|TRPV3_HUMAN ------------------YDLTN----VDTTTDN-SVL------EITVYN-T-N-IDNRH 417 
SP|Q9H1D0|TRPV6_HUMAN ------------------YDLTE----IDSSGDEQSLL------ELIITT-K---KREAR 345 
SP|Q9NQA5|TRPV5_HUMAN ------------------YDLTE----IDSWGEELSFL------ELVVSS-D---KREAR 305 
SP|Q8NER1|TRPV1_HUMAN ------------------YDLSC----IDTCEKN-SVL------EVIAYS-SSE-TPNRH 411 
SP|Q9Y5S1|TRPV2_HUMAN ------------------YDLAS----VDSCEEN-SVL------EIIAFH-C-K-SPHRH 368 
                                         :*:      *:  .  :.        :           .   
 
SP|O94759|TRPM2_HUMAN Q-----KLLTRVSEAWGKTTCLQLALEAKDMKFVSHGGIQAFLTKVWWGQLSVDNGLWRV 756 
SP|Q9HBA0|TRPV4_HUMAN EMLAVEPINELLRDKWRKFG---------------------------------------- 467 
SP|Q8NET8|TRPV3_HUMAN EMLTLEPLHTLLHMKWKKFA---------------------------------------- 437 
SP|Q9H1D0|TRPV6_HUMAN QILDQTPVKELVSLKWKRYG---------------------------------------- 365 
SP|Q9NQA5|TRPV5_HUMAN QILEQTPVKELVSFKWNKYG---------------------------------------- 325 
SP|Q8NER1|TRPV1_HUMAN DMLLVEPLNRLLQDKWDRFV---------------------------------------- 431 
SP|Q9Y5S1|TRPV2_HUMAN RMVVLEPLNKLLQAKWDLLI---------------------------------------- 388 
                             :   :   *                                             
 
SP|O94759|TRPM2_HUMAN TLCMLAFPLLLTGLISFREKRLQDVGTPAARARAFFTAPVVVFHLNILSYFAFLCLFAYV 816 
SP|Q9HBA0|TRPV4_HUMAN ---------------------------------------AVSFYINVVSYLCAMVIFT-- 486 
SP|Q8NET8|TRPV3_HUMAN ---------------------------------------KHMFFLSFCFYFFYNITLT-- 456 
SP|Q9H1D0|TRPV6_HUMAN ---------------------------------------RPYFCMLGAIYLLYIICFT-- 384 
SP|Q9NQA5|TRPV5_HUMAN ---------------------------------------RPYFCILAALYLLYMICFT-- 344 
SP|Q8NER1|TRPV1_HUMAN ---------------------------------------KRIFYFNFLVYCLYMIIFT-- 450 
SP|Q9Y5S1|TRPV2_HUMAN ---------------------------------------PK-FFLNFLCNLIYMFIFT-- 406 




SP|O94759|TRPM2_HUMAN LMVDFQPVPSWC--------------------------------ECAIYLWLFSLVCEEM 844 
SP|Q9HBA0|TRPV4_HUMAN LTAYYQPLEG--TP---------------PYPYRTTVDYLRLAGEVITLFTGVLFFFTNI 529 
SP|Q8NET8|TRPV3_HUMAN LVSYYRPREEEAIPH--------------PLALTHKMGWLQLLGRMFVLIWAMCISVKEG 502 
SP|Q9H1D0|TRPV6_HUMAN MCCIYRPLKPRTNNRTSPRDNTLLQQKLLQEAYMTPKDDIRLVGELVTVIGAIIILLVEV 444 
SP|Q9NQA5|TRPV5_HUMAN TCCVYRPLKFRGGNRTHSRDITILQQKLLQEAYETREDIIRLVGELVSIVGAVIILLLEI 404 
SP|Q8NER1|TRPV1_HUMAN MAAYYRPVDG--LP---------------PFKMEKTGDYFRVTGEILSVLGGVYFFFRGI 493 
SP|Q9Y5S1|TRPV2_HUMAN AVAYHQPTLKKQAA---------------PHLKAEVGNSMLLTGHILILLGGIYLLVGQL 451 
                          .:*                                     .    .  . :      
 
SP|O94759|TRPM2_HUMAN RQLFYDPDECGLMKKAALYFSDFWNK-LDVGAILLFVAGLTCRLIPATLYPGRVILSLDF 903 
SP|Q9HBA0|TRPV4_HUMAN KDLFMKKCP-GV----NSLFIDGSFQLLYFIYSVLVIVSAALYLAGIEAYLAVMV--FAL 582 
SP|Q8NET8|TRPV3_HUMAN IAIFLLRPS-DL----QSILSDAWFHFVFFIQAVLVILSVFLYLFAYKEYLACLV--LAM 555 
SP|Q9H1D0|TRPV6_HUMAN PDIFRMGVTRFF----GQTILGGPFHVLIITYAFMVLVTMVMRLISASGEVVPMS--FAL 498 
SP|Q9NQA5|TRPV5_HUMAN PDIFRVGASRYF----GKTILGGPFHVIIITYASLVLVTMVMRLTNTNGEVVPMS--FAL 458 
SP|Q8NER1|TRPV1_HUMAN Q-YFLQRRP-SM----KTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVASMV--FSL 545 
SP|Q9Y5S1|TRPV2_HUMAN W-YFWRRHV-FI----WISFIDSYFEILFLFQALLTVVSQVLCFLAIEWYLPLLV--SAL 503 
                         *       .       : .   . : .    : :      :         :     : 
 
SP|O94759|TRPM2_HUMAN ILFCLRLMHIFTISKTLGP-KIIIVKRMMKDVFFFLFLLAVWVVSFGVAKQAILIHNERR 962 
SP|Q9HBA0|TRPV4_HUMAN VLGWMNALYFTRGLKLTGTYSIMIQKILFKDLFRFLLVYLLFMIGYASALVSLLNPCANM 642 
SP|Q8NET8|TRPV3_HUMAN ALGWANMLYYTRGFQSMGMYSVMIQKVILHDVLKFLFVYIVFLLGFGVALASLIEKCPKD 615 
SP|Q9H1D0|TRPV6_HUMAN VLGWCNVMYFARGFQMLGPFTIMIQKMIFGDLMRFCWLMAVVILGFASAFYIIFQTEDPE 558 
SP|Q9NQA5|TRPV5_HUMAN VLGWCSVMYFTRGFQMLGPFTIMIQKMIFGDLMRFCWLMAVVILGFASAFYIIFQTEDPT 518 
SP|Q8NER1|TRPV1_HUMAN ALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIEDGKND 605 
SP|Q9Y5S1|TRPV2_HUMAN VLGWLNLLYYTRGFQHTGIYSVMIQKVILRDLLRFLLIYLVFLFGFAVALVSLSQEAWRP 563 
                       *     ::     :  *   ::* * :: *:  *  :  : :..:. *   :        
 
SP|O94759|TRPM2_HUMAN V------------DWLFR---------GAVYHSY---LTIFGQIPGYIDGVNFNPEHCSP 998 
SP|Q9HBA0|TRPV4_HUMAN KVCNEDQTNCTVPT--YPSCRDS----ETFSTFL---LDLFKLTIGM------------- 680 
SP|Q8NET8|TRPV3_HUMAN --------------------NKDCSSYGSFSDAV---LELFKLTIGL------------- 639 
SP|Q9H1D0|TRPV6_HUMAN -------------------------ELGHFYDYPMALFSTFELFLTI------------- 580 
SP|Q9NQA5|TRPV5_HUMAN -------------------------SLGQFYDYPMALFTTFELFLTV------------- 540 
SP|Q8NER1|TRPV1_HUMAN SLPSESTSH----RWRGPACRPPDSSYNSLYSTC---LELFKFTIGM------------- 645 
SP|Q9Y5S1|TRPV2_HUMAN EAPTGPNATESVQPMEGQEDEGNGAQYRGILEAS---LELFKFTIGM------------- 607 
                                                   .       :  *                    
 
SP|O94759|TRPM2_HUMAN NGTDPYKPKCPESDAT-QQRPAFPEWLTVLLLCLYLLFTNILLLNLLIAMFNYTFQQVQE 1057 
SP|Q9HBA0|TRPV4_HUMAN ------------GDLEMLSSTKYP-VVFIILLVTYIILTFVLLLNMLIALMGETVGQVSK 727 
SP|Q8NET8|TRPV3_HUMAN ------------GDLNIQQNSKYP-ILFLFLLITYVILTFVLLLNMLIALMGETVENVSK 686 
SP|Q9H1D0|TRPV6_HUMAN ------------IDGPANYNVDLP-FMYSITYAAFAIIATLLMLNLLIAMMGDTHWRVAH 627 
SP|Q9NQA5|TRPV5_HUMAN ------------IDAPANYDVDLP-FMFSIVNFAFAIIATLLMLNLFIAMMGDTHWRVAQ 587 
SP|Q8NER1|TRPV1_HUMAN ------------GDLEFTENYDFK-AVFIILLLAYVILTYILLLNMLIALMGETVNKIAQ 692 
SP|Q9Y5S1|TRPV2_HUMAN ------------GELAFQEQLHFR-GMVLLLLLAYVLLTYILLLNMLIALMSETVNSVAT 654 
                                   :            :  :    : ::: :*:**::**::. *   :   
 
SP|O94759|TRPM2_HUMAN HTDQIWKFQRHDLIEEYHGRPAAPPPFILLSHLQLFIKRVVLKTPAKRHKQLKN-KLEKN 1116 
SP|Q9HBA0|TRPV4_HUMAN ESKHIWKLQWATTILDIERSFP----VFLRKA---FRSGEMVTVGKSSDGTPDRRWCFRV 780 
SP|Q8NET8|TRPV3_HUMAN ESERIWRLQRARTILEFEKMLP----EWLRSR---FRMGELCKVA-----EDDFRLCLRI 734 
SP|Q9H1D0|TRPV6_HUMAN ERDELWRAQIVATTVMLERKLP----RCLWPR-----SGI-CGRE----YGLGDRWFLRV 673 
SP|Q9NQA5|TRPV5_HUMAN ERDELWRAQVVATTVMLERKLP----RCLWPR-----SGI-CGCE----FGLGDRWFLRV 633 
SP|Q8NER1|TRPV1_HUMAN ESKNIWKLQRAITILDTEKSFL----KCMRKA---FRSGKLLQVGYTPDGKDDYRWCFRV 745 
SP|Q9Y5S1|TRPV2_HUMAN DSWSIWKLQKAISVLEMENGYW----WCRK-K---QRAGVMLTVGTKPDGSPDERWCFRV 706 
                      .   :*: *        .                                        :  
 
SP|O94759|TRPM2_HUMAN EEAALLSWEIYLKENYLQNRQFQQKQRPEQKIEDISNKVDAMVDLLDLDPLKRSGSMEQR 1176 
SP|Q9HBA0|TRPV4_HUMAN DEVNWSHWNQNLG-------------------------------IINEDPGKNETYQYY- 808 
SP|Q8NET8|TRPV3_HUMAN NEVKWTEWKTHVS-------------------------------FLNEDPGPVRRTDFN- 762 
SP|Q9H1D0|TRPV6_HUMAN EDRQDLNRQ---------------------------------------------RIQRYA 688 
SP|Q9NQA5|TRPV5_HUMAN ENHNDQNPL---------------------------------------------RVLRYV 648 
SP|Q8NER1|TRPV1_HUMAN DEVNWTTWNTNVG-------------------------------IINEDPGNCEGVKRTL 774 
SP|Q9Y5S1|TRPV2_HUMAN EEVNWASWEQTLP-------------------------------TLCEDPSGA-GVPRTL 734 
                      ::                                                           
 
SP|O94759|TRPM2_HUMAN LAS-LEEQVAQTAQALHWIV-----RTLRASGFSSEADVPTLASQKAAEE--P------- 1221 
SP|Q9HBA0|TRPV4_HUMAN GFSHT----VGRLRRDRWSSVVPRVVELNKNSNPDEVVVPLDSMGNPRCD-GHQQGYPRK 863 
SP|Q8NET8|TRPV3_HUMAN ---KIQDSSRN-NSKTTLNAFEEV-EE-----FPETSV---------------------- 790 
SP|Q9H1D0|TRPV6_HUMAN QAFHTRG--SEDLDKDSVEKLE-LG-----CPFSPHLSLPMPSVSRST--SRSSANWERL 738 
SP|Q9NQA5|TRPV5_HUMAN EVFKNSD--KEDDQEHPSEKQP-SGAE-SGTLARASLALPTSSLSRTASQSSSHRGWEIL 704 
SP|Q8NER1|TRPV1_HUMAN SFSLRSS----RVSGRHWKNFALVPLL-REASARDR-----------QSA-QPEEVYLRQ 817 
96 
 
SP|Q9Y5S1|TRPV2_HUMAN ENPVLASPPKEDEDGASEENYVPVQLL-QSN----------------------------- 764 
                                                                                   
 
SP|O94759|TRPM2_HUMAN ------DAEPGGRKKTEEPGDSYHVNARHLLYPNCPVTRFPVPNEKVPWETEFLIYDPPF 1275 
SP|Q9HBA0|TRPV4_HUMAN WRT----DDAPL------------------------------------------------ 871 
SP|Q8NET8|TRPV3_HUMAN ------------------------------------------------------------ 
SP|Q9H1D0|TRPV6_HUMAN RQGTLRRDLRGIINRGLEDGESWEYQI--------------------------------- 765 
SP|Q9NQA5|TRPV5_HUMAN RQNTLGHLNLGLNLSEGDGEEVYHF----------------------------------- 729 
SP|Q8NER1|TRPV1_HUMAN FSGSLKPEDAEVFKSPAASGEK-------------------------------------- 839 
SP|Q9Y5S1|TRPV2_HUMAN ------------------------------------------------------------ 
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